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Summary
Access to new markets and lower production costs are some of the reasons why
companies have established manufacturing operations all around the world. These
manufacturing operations may constitute wholly owned factories, joint ventures, as well
as external contractors, forming an international manufacturing network with unique
capabilities. Effective integration and coordination among these operations could become
more and more a pre-requisite in order to survive in an increasing competitive market.
Preliminary contacts with an international pharmaceutical company with significant
activities in Asia-Pacific revealed the company had difficulties in solving manufacturing
location issues efficiently, for new product launches or responding to environment
changes, even though these present a good opportunity for the company to optimise their
chain of locations of the manufacturing operations. In the pharmaceutical case,
manufacturing location decision consists of locating the incorporation into dosage form
step (bulk standard product) and the packaging step (customized finished product).
An extensive literature review reveals two main research gaps:
• The manufacturing location decision literature does not include a network
perspective.
• Manufacturing network literature does not consider extended networks including
wholly owned in-house plants, joint ventures, and external contractors.
This study examines location decisions from a manufacturing network perspective in
order to understand the impact of these decisions for the entire manufacturing network.
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Six retrospective and four longitudinal case studies were conducted over an eight-month
period in the pharmaceutical company, detailing ten product manufacturing location
decisions in Asia-Pacific markets.
The cases confirmed and detailed the importance of the manufacturing capabilities in
product manufacturing location decision-making. They revealed that a manufacturing
location decision is largely driven by the potential benefits drawn from the exploitation
and from the development of the company manufacturing capabilities at both the plant
level and the network level. The drivers, such as plant knowledge or economies of scale
are grouped into four categories: Use of / Development of single site capabilities, Use of /
Development of network configuration capabilities, Use of / Development of network
coordination capabilities, Use of / Development of financial capabilities. More
particularly, it also permitted to identify and detail the influence of the decision specific
context and environment, specified by legislation requirements, markets specifications,
and product specifications, on the role of the previously identified drivers. These drivers
can be classified into qualifying criteria and ranking criteria categories. However, the
relative importance of the drivers is dynamic, varying from one case to another according
to the decision specific factors.
The findings suggest that managers, when making manufacturing location decisions,
should seek to maximize the use and the development of the manufacturing capabilities,
taking into account the influence of the decision context and environment. A simple step-
by-step guide has been developed to assist managers in making the right location decision.
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Access to new markets and lower production costs are some of the reasons why
companies have established manufacturing operations all around the world (Ferdows,
1997b, MacCarthy and Atthirawong, 2003). These manufacturing operations may
constitute wholly owned factories, joint ventures, as well as external contractors.
Collectively, these assets form an international manufacturing network with unique
capabilities. Effective integration and coordination among these operations could become
more and more a pre-requisite in order to survive in an increasing competitive market
(Barlett and Ghoshal, 1988). Of late, there is a trend to relocate products mainly to
concentrate volumes and gain in productivity. It may lead to develop partnerships through
joint ventures or to outsource some part of these production operations. However, while
outsourcing decisions might bring benefits, for instance for production cost, its influence
on long-term capabilities, such as the learning ability might be compromised.
Manufacturing location decisions are no longer only concerned with the evaluation of
independent single site. It now involves many possibilities for which existing
characteristics need to be included in the decision, such as geographical dispersion, type of
entity and interdependency with other entities. Welch and Nayak (1992) stated, “managers
need better tools for evaluating sourcing decisions – tools that can accommodate the long-
term, strategic issues.” There is a need to assess holistically the sourcing decision in
international manufacturing, considering internal and external sources (Karlsson, 2003) by
examining its influence on long-term manufacturing capabilities. This question is
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particularly important in the pharmaceutical industry, where local health regulations often
mean production must be set up locally even though manufacturing capacity might exist
elsewhere. More recently, the emergence of outsourcing as a viable alternative in this
sector further complicates the location decision. Focusing on the pharmaceutical industry,
this project seeks to explore these issues for which existing theories and tools are
insufficient. It will provide managers of international manufacturing companies with
necessary theoretical concepts and a practical process tool including important drivers to
help organizations making manufacturing location decisions.
1.2. Research presentation
Research aims
This research aims to answer the following question:
How can multinational firms efficiently and practically select a location among existing
plants, joint ventures, and local contractors to manufacture a product, with the aim to build
long-term strategic manufacturing capabilities?
In other words, for helping multinational firms to select a product manufacturing location
we have to answer the following questions:
• Which is the most appropriate chain of operations among existing plants, joint
ventures, and external contractors?
• How to consider long-term strategic manufacturing capabilities in the decision?
• How to stay efficient and practical in the decision-making process?
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Research output
The research consists in developing a product manufacturing location decision framework
for a manufacturing company with geographically dispersed facilities, taking into account
not only the financial consideration but also the long-term impact of a sourcing decision
on manufacturing capabilities and using a network perspective, which includes different
type of manufacturing facility such as wholly owned plant, joint ventures and external
contractors. Based on this framework, the research further develops a practical decision-
making tool with the important drivers to help organisations in sourcing decisions.
Structure of the thesis
The organisation of the thesis is detailed in this paragraph and summarized in the
following figure. The thesis is organized in eight chapters as follows.
Chapter 1 constitutes the introduction. It explains the justification of the research,
presents its importance for theory and practice, details its expected outcomes, and finally
gives the structure of the thesis. The literature review in chapter 2 aims to explore the up-
to-date knowledge related to the research objectives and identifies the research gaps. The
research questions are formulated based on the identified research gaps. In chapter 3, the
research methodology is explained. Based on the research issue and the exploratory nature
of the research, a dual methodology case study approach, which includes retrospective and
longitudinal cases, is chosen. Chapter 4, entitled exploratory case, gives a preliminary
presentation of the company studied, the issues involved, and some ideas to draw future
theoretical contents. One case of product manufacturing location decision is detailed to
refine the research questions and obtain contents for the data collection of the future cases.
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Chapter 5 contains the pilot cases and the mapping analysis. This chapter details more
cases, this is to say three retrospective cases. These three cases and the exploratory case
are analysed, permitting to draw categories and map the phenomenon. Chapter 6, entitled
main cases: relationships analysis, constitutes the core of the thesis, presenting the main
cases studied. It consists in two more retrospective cases and four longitudinal cases. The
analysis of all the ten cases permits to validate and refine the previous mapping analysis.
The relationships between the categories are identified and presented in this chapter.
Finally, the findings are presented in a framework for product manufacturing location
decision. Chapter 7, entitled theory validation, presents the research findings in a more
useful presentation for the managers of international companies, namely a workbook and a
5-step tool for product manufacturing location decisions are developed. The theoretical
contents presented in the workbook and the 5-step tool is validated through the evaluation
of expert judgment. Chapter 8, the conclusion chapter, summarizes the key findings,
presents the implications for existing theories and practices. In addition, it identifies
several research limitations and possible future work. Figure 1-1 depicts the structure of
the thesis:
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Figure 1-1: Structure of the thesis
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The literature review aims to explore the up-to-date knowledge related to the research
objectives and identifies the research gaps. The main areas reviewed in this chapter are
manufacturing location decision factors and tools, international manufacturing network
literature and the outsourcing field, particularly for the pharmaceutical industry.
2.2. Manufacturing location decisions
Manufacturing location decisions are decisions concerning the location of manufacturing
activities for a company. It can consist in deciding a new production location, which is
known as plant location decision. Alternatively, it consists in allocating a product within a
group of existing facilities or possible new locations, which is known as product
manufacturing location decision (Vos, 1991). In this section, we first review the literature
about manufacturing location decisions, namely the factors for location decisions and the
tools available. Next, the strategic importance of manufacturing location decisions is
shown through the resource-based and capability-based perspectives of a firm.
Factors for manufacturing location decisions
Manufacturing location decision research mainly focuses on identifying the list of factors
that have to be taken into account for this type of decision. Friedman et al. (1992)
investigated the factors influencing companies in the choice of a specific state within the
United States for setting up a manufacturing plant. The main factors identified are access
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to markets, labour market conditions, state promotional efforts to attract investments, and
state taxes.  Jungthirapanich and Benjamin (1995) conducted a review of the factors
affecting manufacturing location decisions based in previous studies. They classified the
location factors present in the literature into eight categories, presented in Table 2-1.
Category Examples
Market Proximity to markets
Local consumers’ purchasing power
Transportation Land, water and air infrastructure
Labour Labour costs
Availability of local skilled employees
Site consideration Cost of land
Cost of construction
Raw materials and services Availability of raw materials
Availability of business service
Utilities Energy cost and availability





Health and medical support
Table 2-1: Location factors
(Source: Jungthirapanich and Benjamin, 1995)
MacCarthy and Atthirawong (2003) studied the list of factors for manufacturing location
decisions and more importantly their relative importance by using the Delphi method,
which is based on expert judgment. Though not exactly classified in the same categories,
this method confirmed and completed the list identified by Jungthirapanich and Benjamin
(1995). The relative importance of location factors is presented in Figure 2-1, in which the
rating of those factors goes from 1 for not important to 7 for very important.
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Governement and political factors
Economic factors
Legal and regulatory framework
Proximity to markets and customers
Proximity to suppliers
Quality of life
Characteritics of a specific location
Social and cultural factors
Proximity to competition
Proximity to parent company's facilties
Figure 2-1: Relative importance of key factors affecting international location decisions
(Source: MacCarthy and Atthirawong, 2003)
Pongpanich (1999) proposed a different approach for manufacturing location decisions.
He emphasises on the necessity to study this field at a product level instead of a plant
level: a location decision is not where a plant should be located, but where should the
manufacturing of a product be located. Based on this approach, the factors intervening in
the decision are not only location factors for a new plant, but also include capabilities of
existing plants. Thus, Pongpanich (1999) proposed two main categories to classify these
factors: “location appropriateness” and “plant capabilities”. The list of factors established
by Pongpanich (1999) is given in Table 2-2. The factors in the “location appropriateness”
column are very similar to the factors given by Jungthirapanich and Benjamin (1995).
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Table 2-2: Categories of factors for manufacturing location decision
(Source: Pongpanich, 1999)
Despite this contribution, Pongpanich (1999) acknowledges the importance of taking a
network perspective in product manufacturing location decisions. Indeed more and more
companies are operating complex manufacturing networks and are concerned with the
integration of all these assets (Barlett and Ghoshal, 1988). This suggests that location
decision theories should look at the interdependence of the manufacturing facilities and
their integration among the company’s other manufacturing assets. Meijboom and Vos
(1997) highlighted the importance of explicitly considering the issues of coordination
when dealing with manufacturing location decisions and gave preliminary ideas for future
integration of configuration and coordination.
Manufacturing location decision and Supply-chain Management
As shown in the previous paragraph, co-ordination between entities seems to be an
important consideration in manufacturing location decisions. The supply-chain
management field, reviewed in this section, is concerned with this question. In particular,
we explore the literature dealing with the relationships between manufacturing location
decisions and supply-chain management. Several mixed models including location factors
and supply-chain constraints are presented and discussed. The complexity and trade-offs
that emerge when considering sophisticated supply-chain configuration for manufacturing
location decisions are presented.
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In general, supply-chain management deals with the co-ordination between entities along
the whole process from the raw materials to the customer. According to Cooke (1997):
"Supply Chain Management is the co-ordination of all those activities associated with
moving goods from the raw materials stage through to the end user, for sustainable
competitive advantage. This includes activities like system management, sourcing and
procurement, production scheduling, order processing, inventory management,
transportation, warehousing, and customer service."
From the above definition, it is obvious that supply chain management has an impact for
the manufacturing location decision and that both concepts are interrelated. Indeed, Syam
(2002) proposed a model for manufacturing location from the logistic point of view by
considering inventory holding cost, ordering cost, and transportation cost. This model
aims to define optimal manufacturing locations as well as shipment compositions and
shipment cycle times. Sheu (2003) studied the manufacturing location decision as a mixed
issue which includes location and supply-chain factors within a 3-layer environment
(suppliers, manufacturers and distributors). Some of these factors are cost of assembling-
material procurement, transportation costs, storage/inventory costs, manufacturing costs,
restrictions or incentives of local governmental regulations, and the logistical
uncertainties. Although this model presents an interesting approach by combining location
decision with the supply-chain issue, it is still limited as it does not take into account
sufficient location factors to be practically used by managers. In a broader manner, Min
and Melachrinoudis (2003) used the analytic hierarchy process (AHP) to assist managers
in formulating and solving one site relocation decision, taking into account the supply-
chain perspective. They combined 33 factors into six main criteria, namely site
characteristics, total costs, traffic access, market opportunity, quality of living and local
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incentives. Although it includes location factors and supply-chain perspective, this model
only focuses on single site case, missing the opportunity to study the interaction with the
other manufacturing facilities. In contrast, Nagurney et al. (2003) proposed an integrated
framework for modelling complex international supply-chains, including three types of
independent decision-makers, manufacturers/suppliers, retailers/vendors and customers.
They studied the equilibrium (flows and transfer prices) and the dynamics of such
networks. From their study, it can be implied that a manufacturer may relocate itself in
order to optimise its revenues under the network's equilibrium within the global supply-
chain supernetworks.
From these studies, it is obvious that managers facing strategic location decisions have to
consider location factors and supply-chain constraints. One approach is the use of external
logistic companies and service integrators as an alternative to internal logistic operation.
In a study of third party logistics (3PLs), i.e. specialised logistic companies to which a
customer might outsource part or the whole of its transportation, warehousing and
distribution, Tyan et al. (2003) argue that 3PLs obtain various consolidation across their
customers which potentially enable a higher supply-chain performance for their
customers.  (Supply-chain performance is commonly measured in terms of total cost,
responsiveness, flexibility and quality Bahatnagar and Sohal 2003). Some of these
consolidation include inventory consolidation, freight consolidation, and peddling
consolidation (i.e. multiple deliveries to proximate customers) (Syam 2002). These
consolidations, provided by logistic companies, are changing the parameters (lower costs,
better lead-time, broader coverage, etc) of the previously presented models. This change
of environment may lead to questioning previous location decisions and the need of new
solutions with a new optimum location.
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
12
However, introducing new entities in the supply-chain may affect the operational
performance. Indeed, as suggested by Armistead and Mapes (1993), the more different
entities there are in a supply-chain, the more information exchanges are necessary to
ensure quality consistency, low delivery lead-time, ability to change volume quickly and
price. Similarly, Berry et al. (1991) showed the link between supply-chain integration and
performance. When introducing a new partner within the supply-chain, managers have to
ensure they keep the same level of supply-chain integration.
Besides, 3PLs are essentially a compromise between consolidation and the degree of
customer adaptation and might not be able to fulfil all the customer's specifications (Tyan
et al. 2003). Recently, as described by Hertz and Alfredsson (2003), some of these logistic
companies have been moving to more complex and customised services to meet higher
customer expectations.  This new type of logistic service provider, so-called fourth party
logistics - 4PLs, often co-ordinates several 3PLs around the world. Both 3PLs and 4PLs
are examples of supply-chain partners. According to Hertz and Alfredsson (2003),
internationalisation and location decisions of a firm depend highly on :
• the ability of its internal supply-chain to distribute its products for a broader
market or from a new plant location, or
• the firm's ability to develop links with adequate supply-chain partners, able to
answer to environmental changes, or,
• the ability of the firm's supply-chain partners (if any) to adapt to the changes. This
ability may depend on the type of the supply-chain partners. In this case, supply-
chain partners may grow internationally with the growth of their customers.
In other words, complex trade-offs are unavoidable for a firm considering manufacturing
location decision: location decision is tied to the firm's supply-chain development, which
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could be either internal or through partnerships/outsourcing. Similarly, Bahatnagar and
Sohal (2003) studied the relationships between plant location decision, supply-chain
uncertainty and the overall supply-chain competitiveness. Having classified location
factors into eight categories, they surveyed roughly one thousand manufacturing
companies in the Asian countries, regardless of the industry sector, to establish the impact
of location factors on the supply-chain. They revealed the existing trade-offs between
plant locations and supply-chain uncertainty for managers trying to reach the optimal
supply-chain competitiveness. For instance in order to enter a new market, a company
may hesitate between
• developing a partnership with a supply-chain partner able to provide the market
from the current manufacturing plants and,
• setting up a new manufacturing activity locally, possibly enabling a more efficient
supply chain.
In summary, studies have shown that manufacturing location decision has to consider the
consequences of such a decision from a supply-chain perspective, especially when the
company may outsource some activities which add complexity to the supply-chain by
adding new interface / transactions between independent entities.
Manufacturing location decision tools
Existing literature about location decision tools is detailed in this paragraph. These tools
can be divided into two groups, optimisation models, and decision-making tools.
A large number of tools developed for manufacturing location decisions are optimisation
models. They are therefore concentrating on quantitative factors such as production costs,
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capacity, demand quantity, currency exchange rates, material costs, and transportation
costs and are seeking to minimise costs or maximise profits (See Hanna and Newman,
2001, Roberta and Bernard, 1995 for a review of basic quantitative optimisation models).
More elaborated optimisation models (see Revelle and Laporte, 1996 for a review),
integrate additional factors such as risk factors (e.g. Hodder and Dincer, 1986: risk on
currency exchange rates, price uncertainty, and evolution of incentives offered by local
government) or timing of moving production (Tombak, 1995). Optimisation models,
though mathematically interesting, fail to take into account qualitative aspects that are
commonly more important (Meredith, 1992).
On the other hand, decision-making tools are based on a broader approach including
qualitative factors. This group of tools aims to improve plant location decision-making by
developing techniques to deal with the issues. Yoon and Hwang (1985a, 1985b) applied
the multi attribute decision-making method (MADM), which can integrate both qualitative
and quantitative data and helps to select an option from a finite number of possibilities,
which are characterised by multiple attributes. Atthirawong and MacCarthy (2002) applied
the analytical hierarchy process (AHP), which is particularly relevant to tackle multiple
criteria, complex, and unstructured decisions. Jungthirapanich and Benjamin (1995)
developed a knowledge-based decision support system (KBDSS), which incorporates
subjective judgemental evaluations from management, with objective factual location
data. Meredith (1992) pointed out the usefulness of the weighted score model in location
decisions compared with the other models:
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
15
“The most general approach of all is the weighted score model. This approach can combine cost
measures, profit measures, other quantitative measures and qualitative measures in combined
models to help analyse location situations.”
This model is flexible and can include all the qualitative factors that appear to be relevant.
However, Meredith (1992) did not assess the list of factors that would have to be taken
into account for product manufacturing location decisions in the case of international
manufacturing. The methodology developed by Pongpanich (1999), “location matrix”
tool, is derived from the weighted score model and consists of ranking options graphically
along two dimensions (“location appropriateness” and “plant capabilities”) instead of only
one dimension for the classical weighted score model. Decision-making tools are useful
tools for manufacturing location decisions as they permit to incorporate all the relevant
factors in the decision and organise the decision-making process. However, the exactitude
of the results obtained by using these decision-making tools is also subject to the
exactitude of the principles, mentioned in the previous paragraph, namely the list of
factors and the relative importance of those factors, on which they are applied.
Strategic implications of location decisions
Hayes and Wheelwright (1984) stated that manufacturing location decision is an important
element in the manufacturing strategy of firms, as it may contribute to the creation of
sustainable competitive advantages for the firm. Similarly, Bartmess and Cerny (1993)
noticed that,
“A few companies have made location decisions that have fostered the development of
critical capabilities and created lasting competitive advantage”.
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Literature that describes the construction of long-term competitive advantages for a firm is
now abundant. This literature explains the importance of resources and capabilities for a
firm (see Table 2-3 for definitions), as a source of sustainable competitive advantages




A definition of firm’s resource was given by Barney (1991). The resources, assets of a firm,
could be classified into three categories: physical capital resources (facilities, technologies,
and capital), human capital resources (training, experience, and judgment), and
organisational capital resources (reporting structure, planning, and controlling). An
alternative definition, though similar, is the one proposed by Grant (2002), for which
resources are classified into tangible (financial and capital), intangible (technology,
reputation and culture) and human (skills, knowledge, communication and motivation).
Firm’s
capability
Makadok (2001) defines the meaning of firm’s capability as follows. A capability,
• Is a resource
• Is organizationally embedded, non-transferable and firm specific, meaning that it
cannot be bought as an ordinary resource.
• Enhances the productivity of the other resources, helping to reach the full potential




Researchers commonly consider the capability-building process as a process of superior
deployment of resources (Schumpeter, 1950, Makadok, 2001). The capability-building
process contributes to the rent creation of a firm, as benefits obtained by the resources are
enhanced by the capabilities. For instance, the ability to develop a robust and reliable
process for the manufacturing of a specific drug in a pharmaceutical plant (capability) will
enhance the possibility of benefits that are given by the ownership of the patent of this drug
(resource).
Table 2-3: Definitions of firm’s resource and capability, and capability-building process
However, despite its strategic implications, MacCormack et al. (1994) state that
manufacturing location decisions have received limited attention from this strategic
planning literature. Therefore, MacCormack et al. (1994) underlined the importance to
consider factors that evaluate the potential long-term advantages for a manufacturing
location decision. Indeed, they argued,
“Yet location decisions based primarily on cost underestimates the importance of
qualitative factors that are more likely to provide long-term advantages.”
Welch and Nayak (1992), for whom future manufacturing location decision tools have to
incorporate long-term, strategic issues, also express this opinion.
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This section has presented the list of factors and their relative importance that are given by
the literature, for manufacturing location decisions. The literature suggests that the
interdependence of manufacturing entities, part of a manufacturing network, is overlooked
in the existing manufacturing location factors, though it revealed to be an important factor.
This section also detailed the importance to consider manufacturing location decisions as a
strategic issue and concerned with the utilisation and the development of firm’s resources
and capabilities, which is a weak aspect of the existing literature. Thus, future work
should consider location decision with a network and capability based perspective.
2.3. International Manufacturing Networks
As identified in the previous section, a review of the existing knowledge about
manufacturing networks is relevant to develop better theories for manufacturing location
decisions.  Thus, in this section, previous work on manufacturing systems is examined.
One type of manufacturing systems, international manufacturing network, is detailed and
studied more in depth. The capabilities of such manufacturing structure are described.
Definitions
Sule (1988) defined a manufacturing system as the union of facilities such as production
facilities, workers, material-handling equipment, and other supplementary devices. Riggs
(1976) defined a manufacturing system by its function, which is to convert raw material
into finished products and its objective, which is to maximize the productivity. Hitomi
(1994) expanded the classical concept and defined a vertically integrated manufacturing
system that includes the whole process from the market demand to the product shipment.
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This process is represented by four stages: product design including R&D, process
planning, implementation and production management. As more and more companies
have globalised their activities researchers have started to include the international
dimension in their studies. Doll and Vondermbse (1992) explained that the emergence of
global manufacturing players, with their unique geographical dispersion of factories,
permitted to form a horizontally extended manufacturing system no longer constrained by
the factory boundaries. This introduces the notion of international manufacturing networks
(Ferdows, 1989) which could be classified along two dimensions the “vertical integration”
and the “horizontal expansion” (Dicken, 1992).
Presentation of networks
The literature about network organisations is studied here in order to define networks and
classify previously mentioned international manufacturing networks. Snow and al. (1992)
defined network organizations as “clusters of business units coordinated by markets
mechanisms” where each cluster contributing at different stage in the whole process, such
as research, design, and manufacturing to deliver the final product. They characterized
network organizations into three specific types: internal, stable, and dynamic (see Figure
2-2).
• Internal network describes a firm that is not particularly involved in outsourcing
but considers each internal activity as an independent activity realized at market
price and subject to competition with external contractors.
• Stable network is constituted by several firms, commonly constituted by one large
firm and several suppliers. The relationships between the large firm and the
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suppliers are stable. Stable relationships imply a higher reliability of the supply
and better optimisation of the whole organization but on the other hand increase
the dependability and decrease the gain of flexibility brought by the outsourcing.
• Dynamic network characterizes several firms actively involved in outsourcing,
dealing each other on a market-based and commonly short-term relationship.
While dynamic network often permits firms to obtain a high level of specialization
and flexibility, this configuration is restricted to the non-specific activities that can
be outsourced by using a market-based bidding mechanism.
Figure 2-2: Common network types
(Source: Snow et al., 1992)
Dicken (1992) characterized the globalisation phenomenon in two types: the vertical
integration and the horizontal expansion. Consequently, networks can be characterized by
their vertical and horizontal dimensions where the verticality refers to the different layers
of activities and the horizontality to the geographic dispersion of the layers.
Ferdows (1989) explained that in an international manufacturing network, each facility is
serving a specific role network. Ferdows (1989) characterized roles of foreign plants of a
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company in six strategic roles: offshore, source factory, server, contributor, outpost
factory, and lead factory (see Table 2-4).
Role Definition
Offshore To obtain lower production costs.
Source To obtain lower production costs but the plant still has the same ability
to produce as other efficient plants of the network.
Server To reach a specific market with lower tariff barriers or taxes, logistics
costs or currency fluctuation’s risk.
Contributor Server role extended to product and process engineering and supplier
selection and development.
Outpost To collect local information from markets, suppliers, competitors,
research laboratories or universities.
Lead To develop new processes, products and technologies for all the plants.
Table 2-4: Synthesis of the role of foreign factories
(Source: Ferdows, 1989)
Resources and capabilities of manufacturing networks
International manufacturing networks can be characterised by their capabilities. The
description of these capabilities is carried out here, as we saw in the previous section the
importance of the capability-based perspective for the manufacturing location decision.
For a manufacturing network, these capabilities are split into two levels: the plant level
and the network level. As follows:
At the plant level
Hayes and Wheelwright (1984) characterized the resources of a single plant
manufacturing system into structural and infra-structural elements:
• Structural elements refers to the static architectural configurations of the plant:
facilities (size, location, specialization), capacity (amount, timing type) and
technologies (equipment, automation, linkage)
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
21
• Infra-structural elements refers to the dynamic operational mechanisms:
Workforce management (skill development, wage policies, employment security),
quality (defect prevention, monitoring), production planning/material control
(sourcing policies, decision rules), and organization structure (structure,
control/reward system).
These elements are not linked with the location of the plant and only describe the internal
characteristics of the plant that can be abstractly described as a “box” that keep the same
characteristics when moved elsewhere.
The literature commonly agrees on the list of the dimensions of the operational
performance (Hayes and Wheelwright, 1984; Slack and Lewis, 2002), as cost, quality,
delivery, and flexibility. Based on these factors, Pongpanich (1999) suggests the main
capabilities of a plant to consider in a manufacturing location decision are cost,
knowledge, quality, responsiveness, flexibility, and delivery. These capabilities are the
result of a complex mix obtained from the use of and deployment of resource such as
management practices, organizational routines, technologies, and human skills that
contribute in achieving these capabilities. The list of plant capabilities for location
decision is consistent with the definition of the capabilities, which is a resource,
organizationally embedded, non-transferable, firm specific and enhances the productivity
of the other resources. For instance, the ownership of a drug patent, which is a resource for
a pharmaceutical company, is enhanced through those capabilities.
However, the ability to produce at competitive cost not only depends on plant level
characteristics and is a complex result obtained from the characteristics of the plant level
and the network level (Colotla et al., 2002). Firstly, the ability to produce at competitive
cost depends on the plant level through, for instance, plant’s productivity, level of failure
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of equipments, technologies, and process used or cost of equipments. Secondly, this
ability depends on the plant location through factors such as the local cost of labour,
components, and energy, the level of local taxation, and transportation costs between
manufacturing entities, which are all characteristics of the network configuration. Finally,
the ability to produce at competitive cost also depends on the network coordination
through, for instance, the economies of scale across markets, structure of the amortization
of company’s overheads or through the cost of transaction between manufacturing entities
(between the plant and the up-stream and down-stream entities). Thus, it makes sense not
to classify this capability only at the plant level but to consider it separately. Table 2-5
summarizes the main capabilities for a product manufacturing location decision issued
from the plant level given by the literature.
Capability Definition
Knowledge Ability to produce in terms of know-how and process
Quality Ability to meet the quality requirements
Responsiveness Ability to meet the market specifications
Flexibility Ability to be flexible on volume and delays
Delivery Ability to deliver the product (delays and reliability)
Table 2-5: Plant capabilities
(Source: Pongpanich, 1999)
In accordance with the view of a capability-based strategy, the manufacturing strategy at
the plant level should aim to build new manufacturing capabilities and enforce existing
capabilities. Little literature is available about describing the capability-building process at
the plant level. Researchers (See Cua et al., 2001) explain that TQM (total quality
management), JIT (just in time), TPM (total production management), and other best
practices are some resources available for the plants and they could be bought and
implemented relatively easily. However, a superior deployment of those practices is a
capability-building process within the plant that leads to build a hard-to-imitate plant
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manufacturing capability. Schroeder et al. (2002) state that internal and external learning
processes are important to build capability at the plant level and contribute to the
manufacturing performance.
Product manufacturing location decision is supposed to have little impact, if any, on the
capability-building process at the plant level as the consequences of the decision may not
affect directly the practices and organizational routines of the plant. However, product
manufacturing location decision does influence the amount of resources enhanced by the
plant capabilities listed in Table 2-5. Thus, manufacturing location decisions contribute to
the level of deployment of these capabilities and to the creation of competitive advantages.
At the network level
Oliff et al. (1989) defined the configuration of a network as the geographic dispersal of
factories and the coordination of a network as the linkages between the factories. These
two characteristics of a manufacturing network are sources of potential advantages, which
are defined as network capabilities (Porter, 1986). These capabilities characterize the
difference between a sum of independent plants and an integration of interdependent
plants. Cohen et al. (1989) developed a numeric model to optimise the production for
serving several national markets through dispersed manufacturing facilities. Though
highly based on financial factors, such as taxes and exchange rates fluctuation, rather than
strategic issues, this model assesses roughly the capabilities derived from developing the
network characteristic of the manufacturing facilities. It reveals that a network is a means
to reduce costs through economy of scale, to lower tax duties and tariffs and to reach and
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develop strategic markets. Shi and Gregory (1998) and Colotla et al. (2002) proposed a
more detailed list of network resources, based on deep studies of several manufacturing
networks:
• Access to favourable production factors
This capability is mainly derived from the network configuration. It refers to the
ability to access favourable production factors such as low-cost labour, available and
educated workforce, low cost and reliable local energy, proximity to and efficiency of
the local logistic means and the country of origin effect, i.e. “Made in Country X”
label.
• Access to favourable economic, social and political factors
This capability, also mainly derived from the network configuration, refers to the
ability to access favourable local taxation, labour practices, government incentives,
favourable local rules and manufacturing legislation, favourable socio-political
climate, stable exchange rate and low financial risk.
• Proximity to customers and suppliers
Derived from the network configuration, this capability concerns the ability to reach
customers through better responsiveness (mainly transport lead-time) and the ability to
reduce non-value added activities mainly inventories.
• Access to economies of scale
This capability is mainly derived from the network coordination. It refers to the ability
to concentrate volumes of a same product across plants, the ability to obtain a better
return on the firm technologies and investments related to the product. The ability to
standardize products is also a factor that contributes to the economies of scale. The
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
25
ability to focus on significant volume in outsourcing specific products with small
volumes is also an element to achieve economies of scale.
• Access to economies of scope
This capability mainly derived from the network coordination, refers to the ability to
share overhead costs across plants (facilities, information technologies, and human
resources). The ability to concentrate operations and to reduce the duplication of
activities is a means to leverage economies of scope.
• Network flexibility
This capability is mainly derived from the network coordination; it refers to the ability
to change quickly the source of a product, by using standard equipments and
procedure. It also refers to the ability of the network to adjust the capacity to the
demand mainly through a transfer of orders across plants or flexible contracts with
external suppliers.
• Learning ability
This capability is derived from both configuration and coordination. For the
configuration of the network, it refers to the ability to access external learning such as
local technologies, knowledge, and expertise. Through better coordination of network,
firms have the ability to access internal learning: maintaining, developing, and sharing
an internal knowledge and know-how across different plants.
• Access to strategic markets
This capability is mainly derived from the network configuration. It refers to the
ability to reach new markets. It also permits to develop current markets by overcoming
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legal and informal trade barriers and import limitations, and/or through the impact of a
manufacturing presence in the country.
However, these research findings are based on network of plants within a single company,
without considering the external extension of the network. As noticed by Rudberg and
Olhager (2003), research in manufacturing networks traditionally focuses on single
company networks. They underlined the importance for companies to not only master
manufacturing and logistic separately but to integrate the entire value network. Besides,
companies are evolving to structures that involve more and more activities that are
external to the company and a change of perspective is needed for managers to manage
efficiently the continuous organizing of a network (Karlsson, 2003; Shi et al., 2002). Thus,
further research should consider the change of manufacturing organisations’ structure and
extend the manufacturing network field, focusing on intra-firm links as well as focusing
on inter-firms links, as described in Figure 2-3.
Figure 2-3: Manufacturing network and supply-chain
(Source: Rudberg and Olhager, 2003)
This section permitted to identify, that strategic manufacturing decisions and more
particularly product manufacturing location decisions are concerned with the network
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capabilities. As suggested by Colotla et al. (2002), these decisions should involve both the
plant level capabilities and the network level capabilities. However, the capabilities
characterising the international manufacturing networks should be extended to include
more complex external networks, consisting of several organisations, which are
outsourcers for a core firm (Snow and al., 1992).
2.4. Outsourcing
The networks studied in the previous paragraph are internal networks. A study of external
possibilities is detailed in this section. As explained in this section, external possibilities
are classified into joint ventures and external contractors.
The transaction cost approach
With his theory of transaction cost analysis Williamson (1985), set the basis of the
outsourcing theory. He established a characterization of transactions with external entities.
The transactions are classified by using three dimensions:
• Asset specificity: the level of investments for the two organisations in similar
interface equipments, procedures and other specific assets needed to carry out the
transactions involved.
• Uncertainty: the level of ambiguities in the transaction definition (e.g. product,
volume) and performance (e.g. price, delay, quality).
• Infrequency: the inverse of the frequency of which the transactions are
undertaken.
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Figure 2-4: Transaction cost analysis
(Source: Williamson, 1985)
Figure 2-4 illustrates the theory of transaction cost analysis. The further the transaction is
from the centre of the three axes base the higher is the transaction cost. The utility of this
classification is that it brings out elements to define the more relevant type of relationship
with the other organisation and the level of outsourcing. High asset specificity and/or high
level of uncertainty lead to internal manufacturing or co-operative alliance while low asset
specificity, low uncertainty, and low infrequency encourage the market behaviour to
choose suppliers and enable more outsourcing. However, even a medium level of asset
specificity is likely to involve a mid/long term relationship between the contractors, as
significant joint investments may be required to enable the transactions.
Strategic outsourcing
Quinn and Hilmer (1994) took a strategic point of view for outsourcing by including
considerations for potential long-term competitive advantage in outsourcing decision.
They characterized core competency as competency that delivers long-term competitive
advantage, which perform certain activities, which are core to the company. Using this
definition, they stated that these core activities have to be maintained internally and
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protected. The non-core activities can then be considered for outsourcing using the
following methodology.
1. Identification of potential competitive advantages in outsourcing the activity:
specialized contractors often reach a significant size and thus, achieve great
economies of scale; focusing on the process not on a product, they may develop a
higher manufacturing knowledge. Dealing with several customers, they may allow
a higher flexibility than fixed assets.
2. Identification of the degree of strategic vulnerability by stating the critical
elements that have to be controlled and by taking into account the consequence of
a possible market failure.
3. Identification of possible special arrangements with the contractors to reduce the
strategic vulnerability of outsourcing the activity.
Figure 2-5: Methodology for strategic outsourcing
(Source: Quinn and Hilmer, 1994)
The outsourcing matrix, shown in Figure 2-5, determines the type of external solution that
should be implemented for the activity, based on potential for competitive edge and
degree of strategic vulnerability. Ones should also consider the potential strategic risks
raised by outsourcing an activity: loss of critical skills and internal knowledge needed at
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least to manage and control the contractors, loss of potential interactions between
functions which often bring out the innovation and loss of control over a supplier that
acquire enough knowledge to directly enter the market. Figure 2-6 further presents
different types of external possibilities that can be considered in the outsourcing decision,
knowing there might be trade-offs between the level of control and the flexibility
available.
Figure 2-6: Different external possibilities for outsourcing
(Source: Quinn and Hilmer, 1994)
Contractor and Lorange (1988) proposed a similar list of types of inter-organisational
relationships classified along degree of interdependence dimension. Anderson and
Gatignon (1986) classified the different types of inter-organisational relationships along
the level of control for one company. From this literature, these different types of inter-
organisational relationships can be classified into four categories,
• Wholly-owned plant states for full ownership (100% of participation)
• Joint venture states for partial ownership (>50% of participation) and joint
development (50% of participation or possibly less).
• External contractor states for retainer and long-term contract (0% participation)
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• Short-term supplier states for call option and short-term contract (0%
participation). However, this last category is not studied in this research, as the
type of activity studied does not permit to implement these relationships between
two manufacturing entities (Williamson, 1985).
This methodology permitted to identify four categories of manufacturing facilities,
classified by their level of outsourcing for the core company. However, this methodology
alone may not be enough for the managers to identify the potential competitive advantages
of outsourcing, especially in the case of manufacturing networks where numerous factors
are interfering. The network capabilities are a source of competitive advantage in
international manufacturing, thus detailing the influence of outsourcing on those
capabilities is needed to apply this methodology. Besides, the process for such decisions
has to be more developed in order to be more practical and useful for managers facing
outsourcing decisions. For this purpose, the next paragraph details two-process
methodologies for outsourcing.
 Process approach methodologies
Probert (1996) proposed a process approach of outsourcing. This methodology proposes to
assess the critical role of the technologies involved in the manufacturing processes. Thus,
each technology, subsystem, and parts family is evaluated in terms of importance,
competitiveness, impact on product and impact on strategy. This approach enable
managers to determine the non-critical elements of the manufacturing process that could
be outsourced in order to achieve better performance. However, this study does not take
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into account the geographical dispersion of the production in the case of international
manufacturing networks, as “a common condition was that each business was a single
site” (Probert, 1996).
McIvor (2000) proposed a framework that is supposed to be more practical and easy-to-
use for managers. This 4-stage analysis helps managers to choose between performing
internally, outsourcing and investing to perform internally (see Figure 2-7).
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Figure 2-7: A practical framework for evaluating the outsourcing decision
(Source: McIvor, 2000)
However, the four stages analysis involves a deep and demanding study, comprising
• Stage 1: Define the core activities of the business. This preliminary study aims to
define the core activities and non-core activities. As non-core activities should
probably be automatically outsourced, the following stages concern the core
activities.
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• Stage 2: Evaluate the relevant value chain activities. This stage consists of
comparing the potential ability of external sources against the current in-house
performance.
• Stage 3: Total cost analysis of core activities. This stage consists of measuring all
costs generated by sourcing the production either internally or externally. The
output is a comparative cost estimation of the outsourcing case and the internal
case.
• Stage 4: Relationship analysis. This step focuses on defining the best type of
relationship to outsource the activity and on identifying the potential sources for
developing a sourcing relationship.
This methodology gives an interesting step-by-step approach, which may be easier to
tackle, and more practical than previous tools. However, we may need to extend the “cost
analysis” term in stage 3, to include qualitative factors, as factors affecting the capabilities
and performance may not have a quantifiable cost, or may not be easily evaluated without
any questionable assumption. Indeed, “this stage is concerned with identifying all the
activities and costs associated with the outsourcing decision” (McIvor, 2000), a holistic
study to detail the influence of the outsourcing decision on the network capabilities and
performance is relevant.
Outsourcing in pharmaceutical industry
Outsourcing has to be studied more specifically for the pharmaceutical sector as the
specificity of the pharmaceutical manufacturing activities and the situation of the
contracting market may influence the understanding of the issues involved. Outsourcing in
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pharmaceutical companies has been extensively studied by researchers. Numerous
activities within a traditional pharmaceutical company could be outsourced: distribution,
manufacturing, even part of the R&D process through Clinical Research Organisations
(CRO1). The manufacturing process2 in the pharmaceutical sector can be divided into (as
shown in Figure 2-8).
• The upstream process, or primary manufacturing of active ingredient,
• The downstream process, or secondary manufacturing, which can also be divided
into “incorporation into dosage form” and “packaging”.
As identified in Figure 2-8 by boxes with dotted frame, there are four manufacturing
areas, which could be outsourced, production of active ingredients, and incorporation into
dosage form, excipient production, and packaging. While excipient production is
extensively outsourced, Birch (1998) estimates that on average, 50% of the primary
production of active ingredient and 15% of the incorporation into dosage form and
packaging are outsourced.
                                                 
1 See Birch (1998): “A CRO is any company to which a pharmaceutical or biotechnology company can
outsource part or all of the processes involved in the development of a product from compound to market.”
2 Refer to the appendix “the pharmaceutical manufacturing process” for more details.
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Figure 2-8: Drug manufacturing process and outsourcing
(Source: Birch, 1998)
When considering outsourcing a manufacturing activity, it is essential to understand all
the implications for the company (Quinn and Hilmer, 1994). For instance, outsourcing
may allow potential benefits that can be short-term considerations, such as the ability to
access lower costs, but these benefits can be outweighed with side effects that can have
long-term implications, such as the damage of company’s image through quality issue3 or
market launch delay, due to the external contractor.
Birch (1998) proposed a list, shown in Table 2-6, of possible advantages and
disadvantages of outsourcing manufacturing in pharmaceutical companies.
                                                 
3 In April 2003, the Australian health organization suspended the manufacturing license of Pan
Pharmaceuticals, Australia's largest contract manufacturer of complementary pharmaceuticals, citing safety
and quality issues. More than 1,500 products made by Pan Pharmaceuticals have since been recalled,
including the products of the Healthcare and pharmaceuticals company, Mayne Group. A manager of the
company said they did not know how much it would cost to rebuild the reputation of Mayne brands
damaged by the Pan recall (Source: Asia Pulse Limited).
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Advantages Disadvantages
• Active ingredient production could be outsourced
to chemical manufacturers potentially able to
reach higher economies of scale.
• Investing in manufacturing facilities for a product
in development increases the financial risk if the
product fails to reach the finalisation stage.
• Contract manufacturing enables a lower cost entry
into the pharmaceutical sector.
• Contract manufacturers, through a large number
of products within a facility, may better support
overhead costs.
• There may be some opportunities to learn from
the contractor.
• Additional hard-to-plan costs linked with in-
house manufacturing could be avoided (e.g.
validation, regulatory, audits)
• Potential risk of breaching confidentiality and
company’s strategy.
• Consequences of a contractor’s mistake could
be very damaging for the pharmaceutical
company: two critical factors quality and
speed are only fully controlled by internal
manufacturing.
• The contractors market is still immature and
fragmented, leading to the fact that the
pharmaceutical sector hardly find capable
and large contractors.
• The fragmented contracting market and the
critical type of the product imply a high
transaction cost.
Table 2-6: Pros and cons to outsource drug manufacturing
(Source: Birch, 1998)
Piachaud (2002) studied the outsourcing of Clinical Research Organisations (CRO) in the
pharmaceutical sector by surveying large pharmaceutical companies in order to identify
the perceived advantages and disadvantages of outsourcing to CROs in the drug
development process (See Table 2-7).
Advantages Disadvantages
• Obtain greater flexibility and cope with peaks.
• Buy in specialised knowledge and skills.
• Facilitate the rapid exploitation of technology.
• Gain a window on new technology.
• Freedom to concentrate on core functions.
• Spread out risk.
• Reduce costs.
• Improve time to market.
• Dependence on the supplier.
• Lack of shared vision and objectives:
conflict of priorities.
• Loss of control over the supplier.
• Loss of critical skills.
• Problem of evaluating and monitoring
supplier performance.
• Need for a new management mind set.
• Clash of culture.
Table 2-7: Perceived pros and cons to use CROs
(Source: Piachaud, 2002)
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
38
This section reviewed main existing theories about outsourcing and permitted to foresee
some implications for manufacturing location decisions. Knowing that outsourcing the
manufacturing process may bring some advantages but also some disadvantages for the
company, special attentions are needed when considering outsourcing in a product
manufacturing location decision.
2.5. Research gaps and formulation of research question
The literature review permitted to bring out two main research gaps in the field of product
manufacturing location decision for international companies dealing with several types of
geographically dispersed facilities:
• The product manufacturing location decision literature does not include a network
perspective (Meijboom and Vos, 1997).
• Manufacturing network literature does not consider extended networks including
wholly owned in-house plants, joint ventures, and external contractors (Rudberg
and Olhager, 2003).
Therefore and as already explained in previous manufacturing location decision section
and international manufacturing network section, the necessity to study and uncover these
research gaps can be evaluated:
• According to Meijboom and Vos (1997), the companies that overlooked the
coordination aspects between the manufacturing entities often faced unanticipated
problems in operating the plants. Pongpanich (1999) also suggested that the
network perspective in manufacturing location decision tools is more and more
necessary as firms are expending their activities and deal with numerous
geographically dispersed manufacturing facilities. It is important that product
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manufacturing location decision frameworks and tools include a network
perspective (including both configuration and coordination aspects).
• As companies are evolving from internal structures to external structures, a change
of perspective is needed for evaluating manufacturing networks (Shi et al., 2002;
Rudberg and Olhager, 2003; Karlsson, 2003). The network to be considered in
manufacturing location decision research should be extended to external
possibilities such as joint ventures and contractors.
The research question is situated at the intersection of these three fields, as represented in
Figure 2-9.
Figure 2-9: Research question location among existing literature
Thus, considering the importance of the research gaps, this research proposes to uncover
and explore this area in order to fill these gaps. This area can be identified by the
following points:
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• This study explores location decisions of the manufacturing operations for
multinational companies. As location issues are encountered by managers of those
companies, it requires the decision-making process to be efficient and practical.
• The possible locations are not only possibilities within the internal network of the
company but with the whole network, which includes external possibilities such as
outsourcers.
• The research is concerned with the capability-based view of the firm and more
precisely of the manufacturing operations, which is the perspective extensively
used in the International Manufacturing Network literature.
These points raise the following questions:
• Which is the most appropriate chain of operations among existing wholly owned
plants, joint ventures, and external contractors?
• How to consider long-term strategic manufacturing capabilities in the decision?
• How to stay efficient and practical in the process of decision-making?
It permits to formulate the research question:
How can multinational firms efficiently and practically select a location among existing
plants, joint ventures, and local contractors to manufacture a product, with the aim to build
long-term strategic manufacturing capabilities?
2.6. Conclusion
The literature review aimed to explore the up-to-date knowledge related to the research
objectives and to identify the research gaps. The first section explored was the existing
literature about manufacturing location decisions. As the network perspective, taking into
account a large number of potential manufacturing sites and based on the firm’s
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capabilities, was revealed to be useful, but missing in existing literature, the International
Manufacturing Network field was studied, bringing out existing classifications of
networks and their capacities. The outsourcing field was covered as some product
manufacturing location decisions actually imply that the manufacturing is outsourced.
Finally, a review of the literature about outsourcing in the pharmaceutical sector was
carried out. From this literature review, two research gaps were identified, and the
research question was defined.
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In this chapter, the research methodology is explained. Based on the research issue and the
exploratory nature of the research, the most appropriate approach is selected and
presented. A case study, with a dual methodology including retrospective and longitudinal
cases, is chosen and its implementation is described.
3.2. Research approach and method selection
Nature of research question
This study seeks to develop a methodology to guide product manufacturing location
decisions. The focus of the research question is to understand location decisions, not only
the process (how), but also to understand the rationale behind the decision, which requires
understanding the reasons of why selecting a certain location. Understanding the rationale
means discovering, categorizing and eventually linking the variables that have to be
considered in the decision-making process, which constitutes preliminary steps of the
theory-building process. Though the research question mainly focuses on understanding
how, the theoretical foundations have to be discovered in the first place, to support the
identified process (Yin, 1994). Thus, the research approach is exploratory aiming to
initiate a theory-building process, knowing that the choice of methodologies should also
permit to capture the know-how of the decision-making.
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Research approach
As stated in the previous paragraph, we will follow an exploratory approach aiming to
initiate the theory-building process. This approach is split into four stages (Handfield and
Melynk, 1998). The four stages are carried out in this research: discovery and description,
mapping, relationship building and validation. As suggested by Handfield and Melynk
(1998), a fifth stage, would also be necessary to extend and refine the research findings.
However, this stage is not carried out, as it would have supposed to conduct more case
studies in other industry sectors and to use other method, such as the survey method to
generalise the research principles (Please refer to “limitation and further research” section
in chapter 8).
Methods selection and stage deliveries
According to Handfield and Melynk (1998), who suggested preferred research method for
each stage, the selected research method is presented below:
• The discovery and description stage aims to identify research questions from
observations. It consists in an unfocused field study and preliminary retrospective
case (one case). This stage will describe the current situation, the issues involved,
and the first axis of the manufacturing location method.
• The mapping stage aims to identify and describe critical variables. It is
implemented through an exploratory case study, including real time retrospective
cases (three cases). This stage will deliver a list of drivers important in the
sourcing decision.
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• The relationship building stage aims to identify linkages between variables and
causal understandings. It develops the main case studies with the main cases,
retrospective (two cases) and longitudinal (four cases). This stage will confirm and
refine the list of drivers and address the relationships between the drivers and their
relative importance with the sourcing decision.
• The validation stage aims to test the research findings. It consists in implementing
practically the findings derived from the previous stages and validating it from
expert opinions.
The specific case study method used in this research detailing retrospective cases and real
time longitudinal cases is known as the dual methodology for case studies (Leonard-
Barton, 1990). This method combines both retrospective cases and real time longitudinal
cases to compensate for the weaknesses of each type. The approaches between
retrospective and longitudinal cases are slightly different in the way of collecting data and








Low efficiency, danger of data
overload, much unusable data
Relatively high efficiency with
focused data-gathering
b. Objectivity
Danger of too deep involvement,
developing unconscious biases
Danger of unconsciously accepting
respondent bias
c. Pattern recognition
Microscopic examination of details
of process
Recognition of overall patterns in
process
2. Establishing validity




Relatively high internal validity,
good opportunity to establish cause
and effect
Lower internal validity, potential
confusion about cause and effect
c. Construct validity
Opportunity to test sensitivity of
construct measures to passage of
time
Opportunity to validate stability of
construct across situations
Table 3-1: Dual methodology for case study
(Source: Leonard-Barton, 1990)
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Besides, Yin (1994) explained that both history (retrospective case studies) and case
studies are appropriated methods for exploratory works aiming to understand how and why
as described in Table 3-2, confirming that these methodologies will also permit to capture
the know-how.






Experiment how, why Yes Yes
Survey Who, what, where,





how many, how much
No Yes / no
History how, why No No
Case study how, why No Yes
Table 3-2: Research methodologies from
(Source: Yin, 1994)
As shown in this table, a survey approach would not have been appropriate in regards with
the research objectives.
Unit of analysis
Yin (1994) emphasized the importance of the unit of analysis to define the cases to be
studied in a case study. As this study will identify and organize the factors relevant for a
sourcing decision in international manufacturing and will propose a process framework to
help managers in the sourcing decisions, the most appropriate unit of analysis is product
manufacturing location decision case, including internal and external potential sources.
The cases in this study are within a same company and concerning the same
manufacturing activity, thus potential factors derived from the company and the activity
will not intervene in the findings.
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3.3. Data collection techniques
This research follows the proven data collection techniques for each research method
proposed by Handfield and Melnyk (1998). The unfocused field study method is
implemented by exploratory observation, elite interviewing, and reading of archive
documents (e.g. internal reports, minutes of meeting). The data collection for the case
study method is constituted by archive documents (internal reports, minutes of meeting,
unobtrusive measures) and interviews for retrospective cases, and observation through
action research, discussions, and documents for the longitudinal cases. Finally, the data
needed to evaluate the proposed tool is collected through questionnaires.
3.4. Organization of the data collection for the case studies
Sources of data for retrospective cases
The data are basically either “hard” or “soft”. The “hard” data is constituted by all the
documents dealing with the case or the issue in general. Typically, the main documents
are case preparation documents, financial analysis, case review, meeting minutes and
internal reports. This data is gathered by the asking for documents from the people
involved in the cases, looking for relevant documents in the company archive and
accessing internal company on-line information. The “soft” data is all the non-tangible
data, this is to say the knowledge and experience of the people involved in the cases. The
data gathering consists in interviewing these people through formal interviews and
informal discussions, attending meetings, and reviewing cases. The semi-structured
interview protocols that have been developed for both pilot cases and main cases are
enclosed in appendices. The knowledge and experience gathered were put down into
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transcripts. The transcripts were further reviewed by the people involved in the cases, in
order to enhance the reliability. As stated by Voss et al. (2002) concerning the “soft” data
collection:
“There should be feedback and checking of the data, which typically involves presenting the case
description or written-up record of the data to the organization for verification”
The amount of data that could be collected for each case, by these means, depends on the
complexity and importance of each case, because of the various numbers of persons
involved in the preparation and the decision from one case to another.
Data collection for the longitudinal cases
The longitudinal cases give an opportunity for the researcher to complete and validate the
analysis made from the retrospective cases. More particularly, in this study, the
longitudinal cases enable to detail the decision process and specify the true importance of
each driver in the decision, without any interviewee bias. As stated by Leonard-Barton
(1990), real-time study gives a better understanding of the cause-effect relationships than
retrospective cases:
“The most significant limitation of wholly retrospective research is the difficulty of
determining cause and effect from reconstructed events” Leonard-Barton (1990).
The data gathered in the longitudinal cases comes from the researcher, who interacted
informally with the managers who guided the decision preparation and helped to collect
the information needed to prepare the product manufacturing location decisions and
interacted more formally with the head-managers to take the decisions. Thus, the type of
data is constituted by emails, reports, informal discussions and meeting minutes in which
the researcher can be participative. The data is also constituted by the researcher inputs
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and perception of the problem. Though this data could be subjective and biased, this
approach enabled a learning cycle between the retrospective cases analysis and the real-
life (longitudinal) cases: The researcher, based on the retrospective cases analysis, tested
the results in the real-life case and detected some anomalies, leading to improve the theory
and validate it.
3.5. Data analysis procedure
The central procedure used for analysing the raw data is the coding process described by
Strauss and Corbin (1990). This procedure consists of:
• Open coding
• Axial coding and selective coding
Open coding method
This method is the first step to analyse the data. It involves identifying concepts, category,
properties, and dimensions:
• Concepts: Conceptual labels placed on discrete events, and other instances of
phenomena
• Category: A classification of concepts: the concepts are grouped together under a
higher order, more abstract concept called a category
• Properties: Attributes or characteristics pertaining to a category
• Dimensions: Location of properties along a continuum
The open coding process can be summarized into four steps:
1. Labelling phenomena: Conceptualising data is the first step in data analysis
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2. Discovering categories: Categorizing and grouping the concepts through
comparison
3. Naming a category: A category name is a more abstract concept than the ones it
denotes. As stated by Anselm Strauss (1990):
“You can borrow a name from the technical literature. In using them, you may contribute beyond
your own study to add to the importance to the development of concepts that are of importance and
concern within your own discipline”.
4. Developing categories in terms of their properties and dimensions: Knowing
such general properties of a category is important because these give the full range
of dimensions over which a category may vary.
Axial and selective coding method
The axial coding method is similar to open coding but focusing on finding differences,
similarities, and relationships between labels in order to group categories into wider
macro-categories and linking categories together. The selective coding is similar to axial
coding but focusing on one specific category at a time, aiming to uncover missing
relationships and to validate existing links for this category.
3.6. Validation of the means of data measuring
The data validation will mainly rely on the triangulation method (Yin, 1994). This is to
say, multiple sources of evidence through different people are used to validate each of the
important variables.
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3.7. Summary of the research process
Table 3-3 summarises the research process presented in this chapter.
Research
stage







































- Case 5, 6, 7, 8,
9 and 10
Validation Test the findings
and predict
future outcomes
Experiment Open and closed-
ended questionnaires
- Expert opinions
Table 3-3: Summary of research process
3.8. Research scope
Activity scope
The business studied is the conventional drug production in the pharmaceutical industry.
The activities studied are manufacturing activities. The manufacturing process studied is
the elaboration of drugs from the active principle to the packed product. The study will
focus on two activities manufacturing and packaging. The manufacturing is from the
active principle to bulk items (box labelled “incorporation into dosage form” in Figure
2-8). The packaging is from bulk item to finished product items (box labelled “packaging”
in Figure 2-8). The product manufacturing location decision concerns these two activities.
As part of the location decision, these activities can be outsourced, which is mentioned in
Figure 2-8 by the two boxes “contract secondary production” and “contract packaging”.
The transactions involved by sourcing those activities to external contractors are
characterized as highly specific and highly uncertain and imply, as stated by Williamson
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(1985), a stable relationship with contractors. Short-term market-based outsourcing cases
are not in the scope of this study.
Network scope
The network characterized in this study is a manufacturing network as defined by the
literature review, performing the two activities previously mentioned (“incorporation into
dosage form” and “packaging”) and providing specific markets with the above-cited
products. Network nodes are manufacturing facilities constituted by the wholly owned
plants, joint ventures and the contractors as defined previously. Network links are flows
between nodes including physical flows of materials and non-physical flows such as
information knowledge and experience that make the nodes evolutions dependent on each
other. The relationships between the nodes are stable. One main core firm owns the
products and provides the manufacturing facilities with the main components (active
principles). This firm is mainly relying on its own manufacturing facilities (wholly owned
or joint venture) but outsources, for some reasons, some part of its production. This type
of network configuration refers to the stable external network described by Snow et al.
(1992). Moreover, as we are only looking at the manufacturing stage, this network is
horizontal (though we consider two levels in the manufacturing process: manufacturing
stage itself and packaging).
3.9. Research implementation
The type of the case is either retrospective or longitudinal. The three stages in which the
cases are used for the analysis are discovery stage, mapping stage and relationship
building stage, as presented in the following figure (presented in Figure 3-1).
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Figure 3-1: Repartition of cases among the stages
The case studies, conducted during this research, are presented in Table 3-4. For each
case, the different manufacturing and packaging sites that have been studied and the final
choices are mentioned.
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Table 3-4: Cases table
* This column gives the period during which the case had been discussed, prepared, and finally concluded
by the decision (thus, the decision was taken at the end of the mentioned period).
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3.10. Conclusion
This chapter permitted to select the most appropriate methodology to answer the research
question: a dual methodology for case studies, including retrospective and longitudinal
cases. Different stages of the research were identified. The methods to analyse the raw
data were described. In the last section, the scope of the study was specified.
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This stage aims to discover the field studied and provide a structure to organize the
subsequently more focused steps. The first part of this stage is the unfocused field study
providing some unfocused elements about the case company. Then a first preliminary case
of product manufacturing location decision is studied to gain a preliminary understanding
of the decision process and to guide the definition of the data collection protocol for the
next stages.
4.2. Unfocused field study
Asia-Pacific drug market
The Asia Pacific drug market is very much segmented, when compared to other regions in
the world. Indeed, drug legislations, especially in terms of registration procedure or
packing specifications, the import limitations on finished goods, the packaging size
requirements, the market growth and worth, the political and economical instability and
the climatic conditions are some elements contributing to the fragmentation of the Asia
Pacific market almost to the country level. These factors result in a high level of
complexity in the manufacturing facilities, with the existence of dispersed factories and an
extended use of local contractors for packaging and manufacturing the products from the
active principles. Consequently, product manufacturing location decisions concerning
products for those markets are complex and will imply a wide range of factors that may
not be revealed in other uniform regions, such as Europe. This fragmentation of markets
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provides a good opportunity for research in manufacturing location decisions. As stated by
Voss et al. (2002) it is essential to identify contrasted cases with sharp differences in order
to capture the larger range of factors. The study will thus focus on these marketed
countries, as they are a more representative sample of cases to consider for the case study.
Case company in Asia
The case company studied in this dissertation is a worldwide pharmaceutical company,
company X, with significant activities in Asia. The company has a market presence in
many countries in Asia, including Australia/New Zealand (AU/NZ), Bangladesh (BD),
China (CN), Hong Kong (HK), Indonesia (ID), Malaysia/Singapore (MY), Pakistan (PK),
Philippines (PH), South Korea (KR), Thailand (TH), Taiwan (TW), and Vietnam (VN).
The study focuses on the manufacturing and packaging of drugs, namely tablets, from the
active principles. Each product is defined by a brand, which could be a strategic brand that
is sold with similar formulation and packed in several countries; or it can be a local brand
with a specific formulation and sold mainly to a single country.
Current sourcing configurations of the countries
As specified in the internal product source database and reiterated by the regional
Industrial Operations (IO) managers, the different types of sources for the countries can be
split into four types (see columns Table 4-1).
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Australia / New Zealand 0% 79% 0% 21%
Bangladesh 99.7% 0% 0% 0.3%
China 89% 0% 0% 11%
Hong Kong 0% 2% 7% 90%
Indonesia 74% 0% 0% 26%
Korea 82% 7% 0% 11%
Malaysia 0% 17% 3% 80%
Philippines 0% 21% 4% 75%
Pakistan 100% 0% 0% 0%
Thailand 0% 67% 5% 28%
Taiwan 0% 3% 11% 86%
Vietnam 78% 0% 4% 18%
Table 4-1: Countries' sourcing configuration in company X
Each country market can source its products from the country and from outside the
country. The distinction between local and non-local sourcing is important, as this will
have a significant effect on the product manufacturing location decision. Indeed a local
sourcing may permit to lower the import duties, to foster the local market development
and to gain a better responsiveness. The local sourcing can be done through an in-house
plant or an external local contractor if there is no equivalent in-house facility in the
country. The distinction between the two sub-categories is also essential: the need to
optimise the capacity of the in-house plant and the flexibility obtained by using a
contractor are some of the factors that may intervene in the product manufacturing
location decision. In the case of non-local sourcing, it is relevant to distinguish the Asia-
pacific region sources and the rest of the world. Indeed amortization of regional
overheads, better time to market, and higher flexibility may be some factors in the
decisions. The rest of the world category can be split into two categories, though not
directly available in the internal product source database: the source that is already the
worldwide source of the main component (the active principle) and the source that is
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chosen for any other specific reasons. Indeed, this distinction is relevant in the sourcing
decision as sourcing the product from the worldwide active principle source may allow
better economies of scale while another source may be justified for instance by lower
labour costs or the need to amortize a specific investment. The partition between each type
of sources constitutes the sourcing configuration of the country. Table 4-1 shows the
unique sourcing configurations of the Asia-Pacific countries.
This strong difference between the configurations suggests the existence of several drivers
with a different importance from one country to another, leading to the choice of a unique
sourcing solution.
Figure 4-1: 1st elements proposed for the sourcing decision
As described in Figure 4-1, several factors, for which the value is given by the market and
the country, may influence the relative weight of the identified drivers in the sourcing
decision. As the market and the country is case specific, the value of the factors will thus
vary from one case to another. Similarly, and as suggested in the figure, other case
specific elements, such as the case product, which implies a larger list of factors, may be
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identified. As suggested in the figure, these case specific elements could also potentially
influence directly the decision.
Overview of manufacturing facilities
Manufacturing facilities constitute the nodes of a manufacturing network. In the case
studies, they can be either wholly owned plants, joint ventures managed by the company





































Table 4-2: Type of facility for the network studied and its relative markets
The Asia-Pacific facilities are described in more details in this paragraph. Table 4-3 shows
the flows from the manufacturing facilities (rows) to the markets (columns). This table
reveals a noticeable difference of the roles of facilities in the manufacturing network.
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BD CN HK ID MY PK PH KR TH TW VN
Australia (AU/NZ) x x
Bangladesh (BD) x x x
China (CN) x
Hong Kong  (HK) x
Indonesia (ID) x x x x x x x
Malaysia  (MY) x
Pakistan (PK) x x
Philippines (PH) x
Korea (KR) x x x x
Thailand  (TH) x
Taiwan  (TW) x
Vietnam (VN) x
Table 4-3: Product flows from the manufacturing facilities (rows) to market (columns)
Firstly, we notice that for the six plants (in bold in the table), the leading role of the
Indonesian plant as a hub for several markets followed by the Korean plant. The Pakistan
and Bangladesh sites export to other markets to a much smaller extent. The Vietnamese
and the Chinese plants serve only their domestic market. However, these six plants were
set up to serve mainly their domestic market. Secondly, the contractors are local
contractors that serve only the country market. Finally, we notice that the Chinese plant,
established in 2002, is the unique node not to be connected to any way to another node.
However, we could consider it as already connected to the rest of the network as it will
serve several markets once the legislation requirements are approved (3 products are in
process and planned to be approved in 2005 and 2006). It will be allowed to supply Hong
Kong and Thailand with the first product (10million tablets/year) and Australia,
Philippines and Thailand with the second product (75million tablets/year).
These flows of products, connecting the nodes together, are the first basic physical
justification for using a network point of view in this study. This network can be classified
as horizontal as we are only considering the production process, which is constituted of
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manufacturing (“incorporation into dosage form”) and the packaging operations.
According to the literature (refer to Figure 2-2), this network can be described as an
external stable network, where the case company is a core company that owns the
products while the case company provides the outsourcers with the components but still
manufactures and packs most of the products. The suppliers cannot continue to produce
these products without the support of the core company but the core company could do so
without the suppliers. Secondly, relationships with the suppliers are mid-term (typically
from 2 to 5 years) and long-term (from 5 to 10 years) contracts giving an overall stability
to the network.
Company strategy 4
The case company first focuses its strategy on quality and customer service, which are
understood to be the two most crucial prerequisites for a pharmaceutical company. The
next strategic driver is financial, with the objective to increase the earnings per share
(through for instance cost reduction or better time to market) and increase the free cash
flow (through for instance control of inventories or capital spending).
Network perspective in the company
The integration and coordination of the manufacturing network is one of the means to
achieve the goals of the strategy. As stated by the World Head of Supply Chain5:
“In my opinion, the ability to create networks, and then to operate within them, is one of
the most vital prerequisites of the competitive strength of any business operating on a
global scale”
                                                 
4 Source: Industrial Operations Vision & strategy 2002
5 Source: company conference abstract 2002
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Understanding the impact of strategic decisions, including product manufacturing location
decision, for the whole company network becomes more and more a necessity.
Product manufacturing location decisions in the company
The drug manufacturing process is constituted by three layers: the manufacturing of the
active principle, which is the main component (MC) in the drug process; the
manufacturing of the bulk drug from the active principle, which constitutes the standard
product (SP), the packaging to obtain a customized product (CP) from the bulk items (see
Figure 4-2). In the cases studied in this research, due to the structure of the company and
in order to keep the same unit of analysis, the active principle source is always fixed and is
not an element of the sourcing decision but an input. However, the location of the
manufacturing of the standard product and the location of the packaging of the customized









Location decision Location decision
Figure 4-2: The scope of a product manufacturing location decision
External contractors in product manufacturing location decision
Outsourcing part of the manufacturing process, this is to say manufacturing
(“incorporation into dosage form”) and/or packaging, could be a possibility for the
product manufacturing location decision. From the Head of Industrial Operations Asia-
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Pacific’s point of view6, the case company’s approach towards outsourcing of
manufacturing can be summarized as:
• Outsourcing is not a preferred choice
• Outsourcing is done primarily to access special technologies; need of urgent
capacity; or as a consequence of licensing deals
• It is an opportunity to avoid new upgrading investments for old products or non-
strategic products.
• The company will produce in-house when possible to leverage existing capacity.
• Supply reliability and legal / quality compliance issues may outweigh the potential
benefits of lower costs from outside contractors.
• The company has indeed interests in partnering if there are opportunities to
leverage capacity investments and maintain regulatory rigor.
The company may outsource part of the manufacturing process if the following
performance considerations are met7:
• Highly reliable and lower cost supplier is available
• The product quality will not be affected or will be improved further
• Time to market can be improved substantially
• Access to important technology is achieved (if applicable)
• Customer service can be improved
• Back-up capacity for uncertain demand is less expensive outside
• Future capital expenditure and costs can be reduced in order to free up in-house
capacity for new products.
                                                 
6 Source: Contract manufacturing internal conference, Oct 2002
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The evaluation of these factors will be part of the decision making process for product
manufacturing location decisions involving external contractors.
4.3. Preliminary case (Case 1)
Case raw data
Having understood the background and context in which the core company operates, we
then conducted a preliminary case study. The study of the first case is exploratory. Thus,
the main sources of information are mainly from documents as well as informal discussion
with a regional manager. Table 4-4 lists the sources of information for this case.
























Head of Asia Pacific Supply Chain
Table 4-4: Case 1 raw data
Case presentation
The commercial operations in Bangladesh had launched two strengths (1mg and 2mg) of
the case product, a strategic product for the company, nine months ago. The finished
products were imported originally from the company German plant, but the renewal of the
importation license was refused by the local authorities. A reason for this refusal was that
locally manufactured generic products were now available on the market. Moreover, the
commercial operations had planned to launch two other strengths for this product (3mg
                                                                                                                                                   
7 Source: Contract manufacturing internal conference, Oct 2002
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and 4mg) in order to compete generic products with higher potencies and apply the “one
pill per day” marketing campaign. Import licenses for those strengths were also refused.
The objective of this case was to study the possibility to manufacture the product locally
in a joint venture in which the company was already manufacturing some products.
However, the case product, a new strategic product, was only manufactured in Germany
for the worldwide market, and guaranteeing the quality of the drug for every market was
essential for the company’s image. After some studies, it had been decided to manufacture
the four strengths of the product in Bangladesh, as it was the only way to keep marketing
this product and compete against generic manufacturers. A prerequisite of the decision
was for the plant to implement the international Good Manufacturing Practices. However,
a process transfer from the German plant to the Bangladesh plant was initiated to ensure
the equal quality of the drug manufactured in Bangladesh. In addition to the objectives of
accessing the market, overcoming legal restrictions on imports, and to compete against the
generic products, this decision also brought the following:
• The facilities and the capacity were available in Bangladesh and only minimum
investments were needed.
• Local manufacturing helped to share the overheads of the region.
• The transfer process was an opportunity to develop the internal learning ability, by
developing a better networking between the two plants.
• Sales were expected to peak up, as local manufacturing overcomes remaining
informal barriers (tendency to prescribe locally manufactured products).
• No additional drug stability study was needed due to flexible legal requirements,
enabling a short lead-time to implement the solution.
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General learning from the case
This case highlighted the importance of the access to the market driver. The role of the
context, in this case the market structure through the existence of generics and the
legislation which impose a local manufacturing when generics are available, is noticed as
a factor influencing the scope of possible solutions to access the market. This case
demonstrated the importance of the specific location of the plant, which is a result of the
network configuration, enabling the company to access markets and compete against the
generic manufacturers.
However, a more structured and global approach would be relevant in order to ensure not
missing any important aspect in the process of decision-making.
4.4. Conclusion
This stage permitted to obtain some preliminary ideas from the case company to
understand the research question. Namely, we noticed that the relative importance of the
decision’s drivers might vary from one case to another due to the impact of external
factors that have to be specified. We also noticed from the exploratory case that some
factors are important drivers in the decision, but we have to go further to specify a list of
these drivers. These ideas have to be further detailed, refined, and confirmed in the next
stages.
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5. Pilot cases: mapping analysis
5.1. Introduction
This stage aims to explore the product manufacturing location decision in order to map the
phenomenon and to show the relevant key variables driving the decision. This chapter is
organised in the following manner. Firstly, we present the cases 2, 3 and 4. We then
present the analysis of the raw data, using the open coding method. Finally, we conclude
with a summary and link it to the next stage.
5.2. Retrospective case (case 2)
Data sources for the case
Table 5-1 presents the data collected in this case.













Table 5-1: Case 2 raw data
Case presentation
The market concerned is Australia and New Zealand, where the total annual sales of the
case product were 0.8 million of euros, constituted by 30 millions of tablets per year. For
this product, the company had outsourced the manufacturing and packaging of the drug to
an external contractor in Melbourne (Australia). The contractor imported the active
principle (drug main component) from France. For the all range of products that were
outsourced for the Australian and New Zealand markets, the company was using the
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facilities of two external contractors in Australia (the one in Melbourne and one in
Sydney). The case preparation was initiated in early 2002 due to the scheduled end date of
the contract with an external manufacturer by Q1 2003. The relationship with the
contractor in Melbourne who manufactures and packages the case product so far would be
stopped for the main reason that the service of this contractor was poor. The scope of the
decision was to decide what would be imported in Australia (the main component as the
current situation or the finished product or even the standard item), and from which
manufacturing facilities.
The steps of the decision were to identify a few interesting possibilities in order to reduce
the decision’s scope and then to study with more details each of these possibilities to give
arguments for the decision.
The interesting possibilities identified were:
(1) Importing the active principle from France and using the local contractor in
Sydney.
(2) Importing the finished product from France.
(3) Supplying the Indian (Goa) plant with the active principle from France and
importing the finished product from India (Goa).
(4) Supplying the Pakistan plant with the active principle from France and importing
the finished product from Pakistan.
(5) Supplying the Indonesian plant with the active principle from France and
importing the finished product from Indonesia.
The final decision, taken a few months after the project initiation, was to use temporally
solution (2) before the end of the contract with the current outsourcer and to switch as
soon as possible to the solution (3), which will take longer to implement.
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The analysis of the case data, presented later in this chapter, permitted to understand the
arguments to identify the interesting possibilities and the drivers leading to the final
decision.
5.3. Retrospective case (case 3)
Data sources for the case
Table 5-2 presents the data collected in this case.
Type Source name Date Author
Company conference abstract  “Global sourcing
in the pharmaceutical industry – Interdisciplinary
decision-making in complex networks”
June 2002 Head of supply chain
Official company case documents January
2003








One semi-structured interview March
2003
Head of Supply Chain
Asia-Pacific
Discussions




Table 5-2: Case 3 raw data
Case presentation
This case was initiated at the beginning of the year 2002: it concerned a product for
Thailand with a worth of 0.9 million euros per year for 5.4 million tablets. In the initial
configuration, the active principle for this product was manufactured in Italy. This
component was sent to the joint venture in South Korea. This plant was manufacturing the
finished product for its own market and exporting the standard bulk tablet to Thailand.
Finally, an external contractor in Bangkok (Thailand) was selected to do the packaging of
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the product (blistering8 and secondary packaging), according to the Thai market
requirements (see solution 1 in Table 5-3). The main reason for considering a new
configuration for sourcing the product was financial (see Figure 5-1). The Thai operation
of the case company had a negative local gross margin with a negative cash-flow impact.
Indeed, the drug Thai market is becoming more and more competitive, relying extensively
on generic products, which forces the local company to reduce the overall selling prices.
Consequently, this product has a much lower selling price than, for instance, South Korea
and the Philippines, which where also importing this product from the South-Korean
plant.
Figure 5-1: Financial issue in case 3
                                                 
8 the blistering operation is the primary packaging for tablets and consists in packaging the tablets into
blisters
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South Korea had too high standard costs for Thailand, resulting from high transfer price of
active principle, which was necessary to balance profits for the Korean and Filipino
markets. This negative gross margin generated a high tax risk, which external auditors had
expressed, due to the local legislation. Independently, this change of sourcing was an
opportunity to comply with the corporate decision to use worldwide a new formulation for
the tablet. Local health regulation in Thailand requires importing products that are also
sold on the market of the exporting country (free sale certificate). It is a way to ensure that
the drug authorities of the exporting country control the quality of the imported
component and to guarantee the quality of this component. Therefore, only plants
producing for their respective local market constituted potential sources for Thailand.
Taking into account this constraint, the list of possible chains as shown in Table 5-3,
where the first possibility is the current configuration. Except Korea, three sites were
considered: Italy (wholly owned plant), Indonesia (joint venture), and India (joint
venture). For each of these three sites, the packaging could potentially be done in the same
plant (2, 3, and 4) or be kept in Thailand (2’, 3’, and 4’).
No Manufacturing Packaging
1 Korea Thailand
2 or 2’ Italy Italy / Thailand
3 or 3’ Indonesia Indonesia / Thailand
4 or 4’ India India / Thailand
Table 5-3: Possible chains for case 3
The main reasons to keep the local external contractor were access to lower taxation,
flexibility for the packaging, product knowledge, and finally relatively low fees. Indeed,
there is 10% of import duties on the bulk tablets and 20% on the finished goods. Besides,
large packs are common in Thailand (100 unit per pack) as tablets are sold by unit in the
outlets, where the blisters are cut manually. The local legislation also requires specific
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information (impact labels and leaflet), which usually implies the development of a
specific artwork for the secondary packaging (international standard pack not used) or to
“re-stick” manually each box. Besides, Thailand has specific climatic conditions (climatic
zone 4: 30°C and 75% humidity) which require plants to be able to provide an appropriate
packaging in accordance with these climatic conditions. With this packaging, the finished
product may have a longer expiration date. In Thailand, market pressures often require
drug companies to exchange for free obsolete products in the hospitals, thus packaging
permitting a higher expiration date are preferred. Furthermore, local health authorities
require specific drug stability data with controlled climatic conditions (zone 4) in order to
approve the drug expiration date. Plants with a long experience of this product are more
likely to have already conducted such specific studies, which was the case of the external
contractor. Finally, the external contractor was able to provide low fees for this operation.
It was mainly due to its access to low labour cost (compared to Italy and Korea) and its
economies of scale by absorbing capacity with volumes from other customers (first
pharmaceutical contractor in Thailand, selling services to most of the main international
drug companies operating in Thailand). There were two main reasons for not keeping the
local external contractor. Firstly, it was an opportunity to increase the absorption of
company overhead and fixed cost by repatriating volumes, while most of the company’s
plants and joint ventures needed to improve their capacity utilisation rate. Secondly, it
matched with the objective to reduce the complexity of the supply-chain, with a lower
number of different entities involved in the manufacturing process. It was seen as a means
to reduce hidden management costs for this product. Manufacturing and packaging in the
same plant was preferred as it represents fewer potential sources of issue. When dealing
with an external contractor, hidden costs are especially significant as such, configuration
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
73
often implies a duplication of support activities (purchasing, consignee inventory
management, interface between the manufacturing entities or quality audit)
As explained, previously, Solution 1 was no more possible as the decrease of the selling
price, a result of high competition in Thailand, had raised a cash flow issue for this
product due to the local legislation in terms of minimal local margin. Solution 2 was a
favourite option. It permitted to reduce to the maximum extent the supply-chain (only one
entity in the whole process as this plant was also manufacturing the active principle).
Secondly, this site was the historical plant starting to manufacture this product; it had a
great knowledge and experience for the manufacturing of this product, ensuring a low
quality deviation and a higher reliability to deliver the product in time. As the Italian plant
was the manufacturing source for this product for many markets worldwide, choosing this
plant would have permit to benefit from and improve the economies of scale, as one large
batch would be used for more markets. On the other hand, this plant had no flexibility to
provide an adapted packaging at reasonable cost (only smaller packs were available), thus
only the solution 2’ (keeping the Thai contractor for the packaging) was possible. Besides,
on the financial side Solution 2 would have implied higher manufacturing costs and higher
import duties (+10%). The solution 2’ presented the advantage of a better location
between the supplier of the active principle and the customer, thus reducing transport lead-
time and inventories resulting from the transport lead-time.
The Indonesian plant (solution 3 and 3’) was quickly eliminated, as the maximal batch,
size allowed by the manufacturing equipments in Indonesia was too small compared to the
annual volumes, requiring too many batches, which implied a too high cost.
India, the remaining possibility, was still in phase of knowledge transfer with the
historical plant (Italy) to implement the new worldwide formulation, thus a 6 months
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additional lead-time was required compared to the Italian solution. On the other hand, the
plant had the equipment and the flexibility to provide an appropriate packaging. Stability
data for climatic zone 4 were also available as it was requested for the Indian market.
Besides, the manufacturing costs in India, much lower than Korea and a bit lower than
Thailand for the packaging, permitted to outweigh partly the increase of import duties in
case of importing finished goods in Thailand. Thus, Solution 4 became financially
possible, even better financially than Solution 2’; it also had the previously mentioned
significant advantages when the solution is not using the external contractor. One
disadvantage of this solution was that as a joint venture, a part of the profit goes to the
shareholders and those shareholders imposed a higher plant mark-up margin9 (initially
40% and agreed at 25% after almost six months of negotiation) instead of commonly 5%
to 15%, thus limiting the company profits and the ability to manage cash flows for the
company.  Solution 4’ was perceived to be less interesting than Solution 4, as it implied to
keep the local contractor for the packaging in Thailand and did not bring any advantage.
At this stage, the remaining solutions were Solution 2’ and Solution 4 (see Table 5-4).
No Advantages Disadvantages
2’ Master the product process.
High economies of scale across markets.
Keep the local contractor in Thailand for the
packaging, even though capacity is available in
other company’s plant.
Complex supply-chain with geographic
separation of the manufacturing and packaging.
4 Simple supply-chain with the two
operations in the same site.
Low labour costs enable to outweigh the
increase of import duties when importing
finish good in Thailand.
Still in phase of knowledge transfer from the
Italian plant.
Joint venture and higher plant margin, thus
limiting company’s profits and cash flow
management.
Table 5-4: Summary of pros/cons for remaining solutions in case 3
                                                 
9 a plant mark-up margin is the margin added to the plant manufacturing cost to obtain the transfer price to
the next entity (market or another manufacturing facility)
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The opportunity to stop relying on the external contractor, to simplify the supply-chain
and to increase the volumes in the Indian joint venture, eventually leads to choose
Solution 4.
5.4. Retrospective case (case 4)
Data sources for the case
Table 5-5 presents the data collected in this case.
Type Source name Date Author
Official company case
documents




December 2002 Supply-Chain Manager
Taiwan
Documents






April 2003 Head of SC Asia Pacific
Table 5-5: Case 4 raw data
Case presentation
The case product was supplied for the Taiwanese market from an external contractor in
Australia. The bulk tablets of this product were imported from a company’s plant in UK,
itself importing the active principle from a company’s plant in France. However, since a
few years ago, countries stopped to market this product (old product) and Taiwan was the
only country to keep marketing the product. Australia was the only exporter of this
product to Taiwan. The import license authorization in Taiwan was about to expire in Feb
2003 and the renewal of the license would require a so-called certificate of free sales,
confirming that the exporting country is also selling the product for its own market and
thus the exporting country drug authorities accept the full responsibility of the quality. As
this free sale certificate was no longer available in Australia, the renewal of the
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importation license in Taiwan was not approved. Alternatives provided by the Taiwanese
supply-chain were:
(a) Finished goods imported from UK,
(b) Bulk imported from UK and local external packaging,
(c) Active principle imported from France, manufacturing and packaging by an
external contractor in Taiwan.
The two first solutions were refused by the Taiwanese authorities as the free sale
certificate was still missing. The only remaining solution was to have local manufacturing
and local packaging, which started to be studied in December 2002. This solution
presented two main issues. Firstly, the time line for the approval and the implementation
of the project was too short. It would have required producing one year of stock to provide
the market with the product, for the period of project implementation, before the end of
the importation license. This production had to be executed before having the approval of
the corporate organisation for the transfer, which represented a significant risk in terms of
cost for the region. Secondly, if the manufacturing of the product for Taiwan were decided
to be transferred to the external contractor, no in-house plants would still manufacture this
product, raising a risk of quality deviation over years, as no other reference would be
available in-house. Though the NPV was 1 million of euros over 5 years, considering
these risks, it was decided to discontinue this product.
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5.5. First analysis: Open coding method and results
Conceptual frame for open coding method
The open coding method described in the methodology chapter has been used to identify
the drivers explaining the decisions made in the four previous cases. The names of the
conceptual labels, used to code the raw data, come mainly from the literature review or
possibly from the case study itself, when a phenomenon was identified in the data and not
encountered in the literature review. In this second case, the name of the conceptual label
may be an expression used by an interviewee, an expression used within the company, or
even an expression encountered by the researcher in previous work experience. For
instance, labels, such as labour costs or country of provenance effect (see Table 5-8) were
inherited from the literature. On the other hand, a label, such as sustainable source
perspective (see Table 5-8) was chosen during the data collection process after
encountering this argument several times. However, using terms derived from the
literature is often preferred. As, stated by Anselm Strauss (1990):
“You can borrow a name from the technical literature. In using them, you may contribute beyond
your own study to add to the importance to the development of concepts that are of importance and
concern within your own discipline”.
Similarly, Miles and Huberman (1994) suggested that the data reduction in qualitative
studies, through the coding process, partly starts even before the raw data is studied, as the
researcher has to decide often without full awareness which conceptual frame is used for
the conceptual labelling of events. This conceptual frame inherited from the literature, on
which the names of most of the conceptual labels are based, is presented Figure 5-2 and
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directly derives from the literature review chapter, however all the concepts presented in
this figure were not necessarily encountered in the case studies.
Figure 5-2: Conceptual frame for labelling during the coding process
Results
Following the coding analysis method, all the conceptual labels describing the events of
the raw data were first grouped into categories, based on the similarities between those
labels. Then the labels within a category have been compared one against each other. The
differences brought out permitted to define the properties of the categories. The
similarities between labels permitting to form categories (see column 2 in Table 5-6) and
the differences between labels within one category permitting to form different properties
for one category (see column 3 in Table 5-6).
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
79
Category Similarities between labels
within a category
Differences between labels within a category
Decision context
/ environment
The labels naming external
elements that cannot be
modified by the company
and are not dependant from
the company were grouped
in this category.
In this category, the labels were referring to legal
constraints, market characteristics and product
specifications, thus, forming logically three distinct




The labels referring to the
physical manufacturing
equipment of a plant were
grouped in this category.
The labels referring to the type of equipment and the
level of utilisation constituted one property (existing
facilities and capacity available). The labels referring
to the size of the manufacturing lot constituted another
property (adapted size of equipments).
Use of quality The labels referring to the
ability of a plant to provide
a good quality for the
product were grouped in this
category.
Two notions were identified, the value of the quality
at the time of the decision (value) and the perspective
of evolution of the quality over years (constancy).
However, they were grouped into the same property
due to the overlaps encountered in the raw data that
created difficulties to classify labels in one or another
property.
Use of delivery The labels referring to the
ability of a plant to deliver a
product were grouped in this
category.
The labels referred to very different notions
permitting to form easily four distinct properties:
reliability of supply (what is the probability to deliver
the product on time?), production lead-time (what is
the average lead-time necessary to deliver an order?),
source implementation lead-time (what is the lead
time before delivering the first shipment?),
sustainable source perspective (Would the source still
deliver the product in few years?)
Use of
flexibility
The labels referring to the
ability of a plant to be
flexible for manufacturing
products were grouped in
this category.
The labels referred to very different notions
permitting to form easily four distinct properties:
ability to serve market specificity (Is the plant flexible
to provide a specific product?), volume flexibility (Is
the source flexible in terms of minimal volume per
order?), possibility of plant expansion (Is the source
flexible in terms of the evolution of volumes over
years?), urgency responsiveness (Is the source flexible




The labels referring to the
knowledge of a plant,
specifically to manufacture
a product or in general were
grouped in this category.
The labels stating whether the plant was already
manufacturing the product or a similar product
constituted one property (already manufacturing the
product or similar). Labels describing the expertise of
the plant to manufacture the product constituted a
second property (Level of know-how). Finally, labels
referring to the experience of the plant for exporting
the product and the organisation available to support
this activity constituted a last property (Export
experience & organisation).
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Category Similarities between labels
within a category






The labels referring to
factors depending on the
country in which the
manufacturing activities are
located were grouped in this
category.
The labels referred to very different notions
permitting to form easily four distinct properties:
Logistic support (What are the infrastructures in the
country?), country of provenance effect (What is the
effect of the “Made in country X” label?), Labour
costs (What are the labour costs in the country?),





The labels referring to the
strategic objective to
develop the business were
grouped in this category.
Labels referring to the objective to access to markets
and improve sales constituted one property (access to
markets and sales). Labels referring to the objective to
compete against competitors and maintain market






The labels referring to the
location of a manufacturing
activity in regards to the
locations of its suppliers and
customers were grouped in
this category.
The labels referring to the transports lead-time
between manufacturing entities constituted one
property (transport lead-time). The labels referring to
the inventories needed to ensure a continuous supply
despite of the geographical dispersion of the
manufacturing entities constituted another property




The labels referring to
economies of scale were
grouped in this category.
See literature review and
Colotla et al. (2002) for the
definition of economies of
scale.
The labels referring to the possibility to aggregate
volumes constituted one property (aggregation of
identical volumes). The labels referring to the
opportunity or not to have standard products
constituted another property (level of standardization).
Finally, labels referring to the need to amortize a
specific in-house investment to manufacture a product
with enough volume or to outsource constituted the





The labels referring to
economies of scope were
grouped in this category.
See literature review and
Colotla et al. (2002) for the
definition of economies of
scope.
The labels referring to the absorption of overheads
through a wide range of products constituted one
property (overhead absorption). The labels referring
to the duplication of activities derived from the
number of entities in the supply-chain and its
complexity (interface and hidden costs) constituted
one property (number of entity in the supply-chain).
The labels referring to the duplication of activities due
to additional suppliers for a market constituted
another property (number of suppliers for a market).
Development of
learning ability
The labels referring to the
ability to increase the
knowledge of one entity
from the other were grouped
in this category.
The few number of labels did not permit to draw
distinct properties, but the labels were all referring to
the opportunity of transfer projects between entities to





The labels referring to the
ability to modify quickly the
supply configuration were
grouped in this category.
The few number of labels did not permit to draw
distinct properties, but all the labels were referring to
the opportunity to have two source of supply for a
market, thus forming a single property, double
sources of supply.
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Category Similarities between labels
within a category







The labels referring to the
ability of a solution to
provide financial advantages
for the company were
grouped in this category.
The labels referred to very different notions
permitting to form easily three distinct properties:
Cost/unit (What is the sum of all the costs of the
manufacturing operations per unit of product?), local
cash flow & ability top manage cash flows (What is
the cash flow in the marketed country and what are
the possibilities to adjust the split of cash over the
different entities?), net present value: corporate






The labels referring to the
decision itself were grouped
in this category.
The labels referred to very different notions
permitting to form easily two distinct properties:
Level of local operations (What is imported in the
country?) and geographic dispersion of non-local
operat ions  (From where are the components
imported?)
Table 5-6: Creation of categories and their properties
The category names, mentioned in the first column of Table 5-6, are directly derived from
the capability-based manufacturing literature, describing the plant level (Pongpanich,
1999) and network level (Shi et al., 2002; Colotla et al., 2002) and given in Figure 5-2.
However, the category’s name Decision context / environment was chosen by the
researcher during the data collection period, after several iterations and after being
discussed during the interviews to describe external factors, which the managers and the
company assume to not be able to modify. The category’s name Product manufacturing
location decision comes from the location factors literature (Vos, 1991; Pongpanich,
1999). The names of the properties and the respective codes used to analyse the raw data
are presented in Table 5-7. This table also summarizes more specifically, than the
conceptual frame given in Figure 5-2 the different origins of these names of the properties
identified and presented in Table 5-6. Codes are defined to refer more easily to the
categories and their properties in the coding of the next cases.
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These terms were mentioned and used by







It refers to the structural elements detailed
by Hayes and Wheelwright (1984).





The term batch size was used to describe the
size of the equipments in the case company.
Thus, the term, adapted size of facilities was
preferred, as it is less specific (Hayes and
Wheelwright, 1984).






The value term comes from Pongpanich
(1999). The constancy term was encountered
in the case studies to refer to the quality risk
over the long-term of outsourcing, which is
also an element of the strategic vulnerability
in outsourcing (Quinn and Hilmer, 1994).
Reliability (Service rate) RE
Plant level
capabilities literature
The term of service rate was used in the
company to describe the reliability of a









This term was mentioned in several cases by
the interviewees and in the documents. It
was also encountered in the literature as





This term was chosen after iterations by the
researcher to depict the risks over the long-
term to loose control over the entity, which
is also encountered in the outsourcing
literature as level of control (Quinn and
Hilmer, 1994).





It is one characteristic of the manufacturing
flexibility, encountered in the literature and








The term MOQ was commonly used in the
case company to describe the plant
flexibility in terms of volumes, which is





This term is referring to the outsourcing
literature and the level of flexibility (Quinn
and Hilmer, 1994), detailing the possibility






This term was encountered in the case
studies, but is very similar to lead-time
flexibility term used by Pongpanich (1999)
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Name of the properties Code Origin of the name Comments
Already manufacturing
the product or similar
MPR Case studies
This term was encountered in the case
s tudies ,  for  des ignat ing plants
manufacturing the case product.










This term was mentioned in the case studies,
but is also a part of plant knowledge,




















(Jungthirapanich and Benjamin, 1995 and






(Jungthirapanich and Benjamin, 1995 and
Colotla et al., 2002)





(Jungthirapanich and Benjamin, 1995 and







This term was chosen by the researcher to
refer to strategic positions against
competitors (mainly generic products). It is
similar to the term encountered in the
literature as capture/maintain market share













It derives from the transaction cost approach
in outsourcing (Williamson, 1985) and is
part of the non-value added activities due to
the geographic dispersion (Proximity to







(Shi et al., 2002; Colotla et al. 2002)
Level of standardization LST
Network level
capabilities literature








(Shi et al., 2002; Colotla et al. 2002)
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Name of the labels Code Origin of the name Comments
Number of entity in the
supply-chain
NESC Outsourcing
The name comes from the researcher, but
derives from the transaction cost approach
in outsourcing (Williamson, 1985)
Number of suppliers for
the market
NSM Outsourcing
The name comes from the researcher, but
derives from the transaction cost approach







(Shi et al., 2002; Colotla et al. 2002)






This terms was encountered in the case
studies and exists in the literature as
Transfer of orders across plants (Colotla et
al. 2002)
Cost/unit COST Location factors
This term is present in location factors
literature and more especially in
optimisation models (Hanna and Newman
2001).
Local cash flow &
ability to manage the
cash flows
LCF Case studies
This term was chosen by the researcher after
iterations to depict the financial factor
concerned by local cash flows and
management of corporate cash flows.
net present value for the
project: corporate profits
NPV Location factors
This term is present in location factors
literature and more especially in
optimisation models (Hanna and Newman
2001).





These terms were chosen by the researcher
to depict the characteristics of a solution as
described in the case studies.
Table 5-7: Origin of the properties' names
The categories and their properties are summarized in Table 5-8. The dimensions of each
property are commonly obvious (numeric value, low-high, no-yes). The last column of the
table shows in which case the category had a significant role. The cases where the
property has a very strong role are represented in bold characters.
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CATEGORY PROPERTIES CASE








Use of facilities & capacity
(FA)
Existing facilities and capacity available EFA,
Adapted size of facilities (batch size) ASF,
1,2,3,4
1,2,3,4
Use of quality (QU) Value and constancy VQU 1,2,3,4
Use of delivery (DE) Reliability (Service rate) RE,
Production lead-time PLT,
Source implementation lead-time ILT,





Use of flexibility (FL) Ability to serve the market specificity SMS,
Volume flexibility (MOQ: mini order qty) MOQ,






Use of / Development of plant
knowledge (PK)
Already manufacturing the product or similar MPR,
Level of know-how LKH,




Use of favourable production,
economic, political factors
(FPF)
Logistic support (access, proximity to logistic hub) PLS,







Use of / Development of access
to strategic targets (ST)
Access to markets (sales) MAR,
Ability to weaken competitors COM
1,3,4
1,2
Use of proximity to customers
and suppliers (PCS)
Transports lead-time TLT,
Inventories level along the supply chain INV
2,3
2,3,4
Development of economies of
scale (ESA)
Aggregation of identical volumes AIV,
Level of standardization LST,




Development of economies of
scope (ESO)
Overhead absorption OHA,
Number of entity in the supply-chain NESC,











Use of double sources of supply DSS 3
Use of / Development of ability
to provide financial advantages
(PFA)
Cost/unit COST,
Local cash flow & ability to manage the cash flows LCF,






Level of local operations (low-high):
(What is imported?) LOP
- Low: Import of the customized product (CP)
- Medium: Import of the standard product (SP)
- High: Import of the main component (MC)
Geographic dispersion of the non-local operations (y/n)
(From where is it imported?) NLOP
- No: Import from the main-component factory
- Yes: Import from an other country factory
1,2,3,4
Table 5-8: Open coding results for the 4th first cases
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5.6. Conclusion
The mapping stage permitted through three exploratory retrospective cases and the
preliminary case to identify several categories of concepts involved in the product
manufacturing location decision. These categories were defined through their properties.
Most of these categories seemed to constitute the drivers that could affect the product
manufacturing location decision. The decision context / environment category appeared to
be specific compared to the other categories as this category is not directly a driver of the
decision but contains all the given elements. This stage delivered a first draft of the drivers
that could be relevant to understand the product manufacturing location decision. The next
stage, which is the core of the study, aimed to validate the existing categories, to refine the
existing, possibly to discover new categories, and to discover new properties. To reach
this objective the open coding method was used. The other purpose of the next stage was
to link the previously discovered categories between each other and to group and to
organize those categories in few more conceptual categories.
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6. Main cases: relationship analysis
6.1. Introduction
This stage aims to validate the previous categories, to modify or to add some categories
and finally to detail the process of the decision by identifying relationships between the
categories. For this purpose, six new cases were conducted.
6.2. Longitudinal case (Case 5)
Data sources for the case
Table 5-5 presents the data collected in this case.
Type Source name Date Author
Registration rules Indonesia February 2003 Registration Officer Indonesia
Implementation planning February 2003 Supply-Chain Manager Indonesia
Packaging specifications February 2003 Supply-Chain manager Thailand
Registration rules Philippines February 2003 Supply-Chain manager Philippines
Cost comparison study April 2003 Researcher & financial managers
Official company case
document
April 2003 Head of SC Asia-Pacific
Report on the location case April 2003 Researcher
Documents
Philippines Generic Law March 2003 Department of Health of Philippines
General approach for
location decision
January 2003 Head of Industrial Operations Asia-
Pacific
Indonesia supply issue February 2003 Supply-Chain manager Asia-Pacific
Informal discussion about the
case
March 2003 CFO Thailand
Discussions
France supply issue April 2003 France plant manager
Meeting Industrial
Operations
(Attended by the researcher)




(Attended by the researcher)
April 2003 Head of Industrial Operations AP,
Head of Supply Chain AP
Table 6-1: Case 5 raw data
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Case presentation
The case concerned the supply of the product X for Australia (11 million tablets per year),
Thailand (5.5 million tablets per year), and Philippines (1.1 million tablets per year). The
study was conducted in the same time and within the same project for three markets but in
a way it can be understood as three sub-cases as the final decision in terms of location
very from one market to another. The current configuration was to import the bulk item
from France and rely on an external local contractor in each country to pack the product
according to the market requirements. It has been decided in early 2003 to review the
current configuration as a potential project aiming to increase the capacity utilization rate
of the in-house plants in Asia-Pacific. The sites identified as potential plants were France
(current sourcing), Indonesia, and Pakistan (Asia-Pacific sites). These sites were selected
as they were already producing the product for their own markets and they were in-house
plants, as the objective is to increase the in-house capacity. However, Pakistan was
eliminated, as the issue of political stability caused doubt in its ability to deliver the
product over years and the ability to manage the transfer properly.
For the Australian market, it has been noticed that the use of an external contractor for
packaging did not rely on any significant justification. Importing a finished product from
France or Indonesia was preferred as this increases the in-house capacity utilisation as
well as reduces the complexity of the supply-chain. For Thailand, the importation of
finished goods was taxed by 20% while import duties on bulk items were only 10%.
Moreover, the competitive market in Thailand had led to a low margin situation, in which
an increase of 10% of costs was hardly bearable. This market situation and the import
legislation implied that to maintain access to the Thai market, the local contractor for the
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packaging had to be maintained. Thus, the product would have to be imported bulk from
either France or Indonesia and the packaging would be done by the local contractor in
Bangkok. For the Filipino market, two external factors were important: the volume of
sales was low for this product; the “generic law” implemented in Philippines implied to
have a specific artwork for the packaging. These two factors highlighted the importance to
choose a flexible site for the packaging, able to provide a specific box design for small
volumes with an appropriate minimum order quantity. It was noticed that the French plant
did not have this flexibility, thus the remaining possible solutions were either the current
situation (France + Philippines) or importing the finished product from Indonesia, which
was able to provide the required flexibility. However, in this case it was preferred to
import the finished goods from Indonesia to lower the complexity and concentrate the
manufacturing issues in the Indonesian plant, rather than involving two entities.
Finally, it has been decided to choose Indonesia for the manufacturing stage for the three
countries. The packaging for Philippines and Australia would also be carried out in
Indonesia. Only Thailand maintained its contractor for the packaging. Some arguments for
this decision among the previously mentioned possibilities were:
- Simplify supply-chain in the case of Philippines,
- Increase capacity utilisation in Indonesia and concentrate more packaging volumes
in one site,
- Develop a new in-house low cost source for the Australia market,
- Provide some financial advantages,
- Improve the reliability of the supply.
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6.3. Retrospective case (Case 6)
Data sources for the case
Table 6-2 presents the data collected in this case.
Type Source name Date Author
Documents Official company case
documents
May 2002 Head of Supply Chain Korea &







Table 6-2: Case 6 raw data
Case presentation
Hypertension treatments use more and more combination drugs, combining two different
active principles together in one pill. Indeed, it often appears that prescribing only one
active principle is not effective enough, and increasingly two medications are prescribed
to patients. In order to improve treatment’s efficacy, patient satisfaction and eventually the
probability for the doctor keep prescribing this product, combination drugs are now
developed and steadily launched on markets by pharmaceutical companies. This case,
finalized in May 2002, concerned the launch of a combination drug for hypertension for
the Korean market with forecasted sales of 5 million tablets per year, namely 2.5 million
euros per year, in early 2003. The case was to decide the locations (manufacturing and
packaging stages) for this product to supply the Korean market. The possible chains
studied were logically, firstly both manufacturing and packaging in the Korean joint
venture (solution 1 in Table 6-3), secondly as for some other markets supplied with this
product, manufacturing by an external contractor in Sweden and packaging in the wholly
owned plant Germany (2). Finally, another possibility was to pack in Korea with imported
bulk tablets from Sweden (3).
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Table 6-3: Possible chains for case 6
While manufacturing common tablets requires standard equipments which could be used
for a wide range of product, manufacturing combination drugs requires very specific
facilities and knowledge. While Korea had a manufacturing plant, they did not have the
capability to manufacture combination drugs. In fact the only plant able to manufacture
this kind of product within the manufacturing network was an external facility (Sweden),
belonging to a competitor, and supplying this product in bulk tablets to the German in-
house plant. Considering the heavy cost of investments, the lack of internal expertise
needed to manufacture the product in an in-house facility and the limited perspective of
development for such combination drugs it was decided to study the possibility to supply
the market from the German plant with the tablets manufactured externally in Sweden.
Eventually, the decision concerning the product location was to decide the packaging
location, either in Germany or in Korea (possibilities 2 and 3).
The main arguments to choose a packaging in Germany were, firstly, the opportunity to
benefit from an increase of economies of scale for the packaging process, as the German
plant was already supplying finished products to several markets (Germany, Australia,
South Africa, Lebanon, Greece, UK, and Mexico). Secondly, the possibility to obtain a
simpler and thus more robust supply-chain for Korea, limiting potential management
issues in Korea and the duplication of activities. On the other hand, the main argument to
choose a packaging in Korea was to overcome some informal barriers on the importation
of finished product in Korea. Indeed imported finished products face difficulties in
gaining authorities approval to be added in drug formularies of major national hospital.
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Besides, there is a remaining strong nationalist sentiment which impacts negatively the
sales of imported finished products, particularly in the case of non customized (language,
labels) packaging. Another reason for favouring packaging in Korea was that it would
help to increase the capacity utilization of the Korean plant and to bear the fixed costs
(overheads, investments) which were, at this time, hardly supported with the local market
and limited export volumes. Finally, it permitted to benefit from the flexibility of the
Korean plant in terms of packaging and the ability to provide a specific packaging
matching with the previously mentioned market expectations.
It was eventually decided, considering all these arguments, to import the bulk item in
Korea and to pack it locally with the main aim to maximize the potential of sales.
6.4. Longitudinal case (Case 7)
Data sources for the case
Table 6-4 presents the data collected in this case.
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Type Source name Date Author




Head of Drug Product quality
operations AP
Supply-Chain Manager Thailand
Regulatory affairs Director Thailand
Chief Financial Officer Thailand
Proposed manufacturing
locations
March 2002 Head of Supply-Chain Asia Pacific
Product status Indonesia March 2003 SC Manager Indonesia
Manufacturing possibilities in
Bangladesh
April 2003 Supply-Chain manager Bangladesh
Stability requirements in
Thailand
April 2003 Thailand Regulatory affairs director
Financial analysis May 2003 CFO South Asia,
Report on location case June 2003 Researcher
Market constraints in Malaysia April 2003 Head of Supply Chain Asia Pacific
Packaging available and MOQ
in Spain
April 2003 International market manager in Spain
Stability available in Bangladesh April 2003 Head of Quality Operations
Bangladesh
Documents
Details of stability requirements April 2003 Regulatory Affairs director Thailand
Product specificity March 2003 Head of Supply-Chain Asia Pacific
Discussions
Market constraints in Thailand April 2003 Supply-Chain Manager Thailand
Meetings
Minutes meeting
(Attended by the researcher)
June 2003 CFO South Asia, Head of Supply-
Chain Asia Pacific, Supply-Chain
manager
Table 6-4: Case 7 raw data
Case presentation
A corporate change of the safety-risk classification of the case product implied to review
the manufacturing facilities used to manufacture this product. In Asia-pacific, this product
was marketed in Thailand (2 million tablets per year), Vietnam (10 million tablets per
year) and Malaysia / Singapore (1.5 million tablets per year). For Thailand, the product
was manufactured and packed locally by an external contractor from the active principle
imported from France. Vietnam, Malaysia, and Singapore were all importing the finished
product from the in-house plant in France. The safety issue was also an opportunity to
optimise the supply configuration for this product. The audit of the manufacturing
facilities revealed that the contractor in Thailand needed to upgrade some of its facilities
to handle safely the sensitive component involved in the production of this drug. Other
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alternatives would be to import the bulk item or the finished good from other plants. In
that case, plants already manufacturing and marketing the product for their domestic
market were preferred as they were able to deliver the free sale certificate required by the
Thai legislation to acquire the drug importation licence. In-house plants in Indonesia,
France, Spain, and Bangladesh were potential candidates with the appropriate facilities
and capacity.
The cost of upgrading the facilities in Thailand was too heavy for the contractor. Knowing
the small volume concerned, thus it has been decided to import the product in another
form from a company plant. In Thailand, the importation duties on raw materials are 1%
of the value, and there are 10% on bulk and 20% on finished goods. Considering the
overall low margin situation in Thailand, it was decided to limit the possible increase of
the import duties to 10% to enable the company to keep marketing this product. Thus, the
contractor in Thailand had to keep carrying out the packaging operations. The financial
study revealed that Vietnam had a very competitive transfer price from France and thus
any change was not financially interesting. For Malaysia and Singapore, the potential
savings were insignificant because of the small volumes and thus it was not really worth
to transfer. Finally, for Thailand, it was decided to eliminate the Bangladesh option, as it
appeared to be a non-suitable source and to eliminate Indonesia because of the high costs
induced by the chain of operation. The remaining option assuring the highest gross margin
was choose, namely to import bulk from Spain and only keep the packaging in Thailand.
6.5. Longitudinal case (Case 8)
Table 6-5 presents the data collected in this case.
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Type Source name Date Author
Packaging possibilities Korea March 2003 Supply-Chain Manager Korea
Importation restriction
Philippines
March 2003 Director Special projects
MOQ in Korea April 2003 Supply-Chain manager Korea
Registration in Philippines May 2003 Regulatory affairs manager
Philippines
Stability available in Korea May 2003 Regulatory affairs manager
Korea
Official  company case
documents
June 2003 Head SC Asia-Pacific
Documents
Report on location case July 2003 Researcher




May 2003 SC manager PhilippinesDiscussions
Packaging flexibility
Philippines
March 2003 General manager Philippines
Table 6-5: Case 8 raw data
Case presentation
The Filipino entity was relying extensively on a local contractor for the packaging of its
products. A reason for using an external contractor for the packaging was the need of
flexibility to pack the relatively small volumes (mainly derived from the legislation
requirements imposing a specific artwork for the secondary packaging (boxes) to conform
to the “generic law” and imposing an appropriate primary packaging (blisters) to suit the
local climatic conditions, supported with stability studies). The case consisted to review
the justification of this configuration for the two main products marketed in the country,
for which the volumes (7.5 million tablets / year) were significant enough to worth study
and implement a change in the supply. These two products were imported bulk from
Korea and packed locally in Philippines by the external contractor. Though other plants
could have also provided Philippines with the finished products, it had been decided to
focus on the possibility for Korea to do also the packaging. Indeed Korea was already
facing a low capacity utilisation rate and would have hardly supported to loose some
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products currently manufactured for Philippines. Knowing that Korea was able to provide
to a certain extent the flexibility required, the main reasons to import directly the finished
products from Korea were to:
- Simplify the supply-chain and reduce supply issues in Philippines,
- Aggregate with the Korean volumes by standardising to the greatest extent the products
for Philippines (in the boundaries of the legislation and market requirements),
- Reduce non-necessary inventories by reducing transport lead-times along the chain,
- Reduce minimum order quantities between the entities,
- Benefit from data-supported know-how in Korea, justifying longer product expiration
dates for the Filipino market, enabling to reduce obsolete issues.
For these reasons and considering that the decision had no financial impact, these products
were to be imported as finished products from Korea.
6.6. Retrospective case (Case 9)
Data sources for the case
Table 6-6 presents the data collected in this case.
Type Source name Date Author
Official company
case documents
October 2001 Head of IO Indonesia, Head of
supply-Chain Asia Pacific
Documents





May 2003 Supply-Chain Manager Indonesia
Table 6-6: Case 9 raw data
Case presentation
The product studied in this case, was to be marketed in Indonesia in four strengths (from
1.25mg to 10mg). The expected volumes one year after the launch were 6.5 million tablets
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equally distributed among the three lowest strengths and 0.2 million for the 10mg
strength. The Indonesian import regulation limits strictly the importation authorisations, if
a local alternative could be possible. Some reasons not to have a local manufacturing are:
- a specific technology, not available locally, is needed
- too small volumes, which make local manufacturing uneconomical
In this case the local manufacturing was a necessity to access to the market, at least for the
three lowest strengths, as no significant reason would have justified importing finished
products. The facilities and the capacity were available in Indonesia, and a process and
knowledge transfer from the Italian plant, “mother-plant” to the Indonesian plant was
implemented. For the 10mg strengths, as the volumes were small, but large enough for the
authorities to ask at least for a local packaging, it had been decided to import the bulk item
from Italy and do the packaging in the Indonesian plant. Other non-leading arguments to
support this decision were:
- Lower labour costs and lower import duties
- Possibility to aggregate the manufacturing with volumes for other countries for the
10mg
- Increase of overhead costs and fixed costs absorption in Indonesia
6.7. Longitudinal case (Case 10)
Data sources for the case
Table 6-7 presents the data collected in this case.
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Type Source name Date Author
Stability requirements Malaysia May 2003 SC manager Malaysia
Manufacturing possibility for
Malaysia
April 2003 Head of Supply Chain US, Head of SC Asia
Pacific, Regulatory affairs director Malaysia
Market constraints in Korea April 2003 Supply-Chain manager Korea
Manufacturing possibility
Indonesia
April 2003 SC Manager Indonesia, Industrial project
manager Indonesia




May 2003 SC manager Brazil
Documents
Report on location case July 2003 Researcher
Discussions Market constraints in Malaysia April 2003 Head of Supply Chain Asia Pacific
Meetings
Meeting minutes
(Meeting attended by the
researcher)
May 2003 Head SC US, Head SC Asia Pacific, SC
Manager Korea, Drug registration Korea
Table 6-7: Case 10 raw data
Case presentation
The case concerns the launch of a product in the Malaysian and Korean markets with
volumes of 0.1 million per year and 4 million per year respectively. This product was
manufactured only in the US plant, as the manufacturing process required a very specific
equipment. Besides, this product was a strategic product, for which the production was
centralized to ensure a high control of the quality and the delivery of the drug. The case
was to decide the location of the packaging operations for these two markets.
For Malaysia, the main issue was to import from a site providing data to support the
stability of the drug in tropical climatic conditions with the packaging used. Indonesia was
the preferred source for Malaysia: The plant had an adapted packaging for this product
and was a convenient location, enabling short transport lead-times. Besides, it would have
helped the region to absorb its fixed costs. However, drug registrations had been refused
by the Malaysian authorities for product manufactured in Indonesia, in response to some
refusals from Indonesia to register pharmaceutical products imported from Malaysia. The
only site able to provide an adapted packaging was Brazil. An investment in the US plant
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was also mentioned but this possibility was eliminated due to the too small volumes
concerned to justify this investment. The Brazilian site was selected, though this solution
raised some issues.
For Korea, the main constraint was the market specifications. They need a specific pack
size (4tablets per pack) while common packs are larger (10tablets per pack at least). The
Korean plant would have been a good possibility for the packaging, but this possibility
was legally impossible as the Korean plant was already packaging this product under
another brand name, and could not pack the product under a second brand name. Some
alternatives were the in-house plants in Indonesia or United States and an external
contractor in Australia, already packaging this product for the Australian market.
However, the external alternative was eliminated, as the contractor was not used to export
and to deal with foreign customers. Besides, it would not benefit the in-house plants,
which could absorb this volume. The two remaining solutions at this stage were US and
Indonesia. The main argument to choose between the two options was the financial study.
The study showed that Indonesia needed a lower investment and was able to provide
lower manufacturing costs. Consequently, Indonesia was selected to produce for the
Korean market.
6.8. Cases analysis: mapping results
The open coding method was used for all the cases to validate and improve the results
from the mapping stage. Most of the categories found in the previous chapter were found
to be relevant to a large number of cases. However, some categories were only represented
in very few cases. Besides, the last six cases of the “relationship building stage” permitted
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Logistic support (access, proximity to logistic hub) PLS,
Country of provenance effect CPE,
Labour costs LAB
Local taxation TAX
Political instability PIN **
Development of network
flexibility (NF)
Use of double sources of supply DSS
Create new links between entities CNL **
Table 6-8: Refined categories
**Newly identified properties
First, the role of the political instability has been identified and classified as a property of
the “Use of favourable production, economic and political factors” (FPF), because this
factor is also directly related to the country of the manufacturing operations. Second, the
category “development of the network flexibility” (NF) was also detailed with an
additional property “Create new links between entities”: a decision, developing new
source for a market, enables a higher flexibility for other following cases as a wider range
of possibilities becomes possible with lower risk and cost to implement these possibilities,
if some products are already sourced from there.
6.9. Cases analysis: relationships results
As explained in the research methodology chapter, the axial coding method aims to
uncover relationships between categories. These relationships can be similarities and
differences between categories, permitting to categorize them in wider groups, or these
relationships can be cause-effects links.
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Categorization results
The axial coding method was used to uncover specific relationships between the identified
categories, namely differences and similarities between categories. These relationships are
identified by comparing the coding labels with one another. Bringing out these
relationships enables to group some similar categories together and to differentiate one
group from another. These categories are presented in Figure 6-1, relationships between
these categories are given later in this chapter.
Figure 6-1: Groups issued from the categorization process
• The first categorization to be made comes from the observation that a large number of
labels are drivers, which lead to the final decision. It permits to construct two
conceptual groups: the group of drivers, which drive the decision, and the category
constituting the decision itself, the product manufacturing location decision.
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• These drivers are characterised by a noticeable similarity: they are all arguments to
evaluate a solution among different possibilities. In contrast, the category decision
context and environment is independent of the possible solutions; this category is
defined by properties that are external to the scope of solutions. This category forms a
group by itself.
• As the group of drivers appears to contain a large number of drivers, it is possible to
identify sub-groups of drivers. First, a number of drivers, listed and detailed later, are
related to evaluating a manufacturing facility in terms of its capabilities. It permits to
group these drivers into one single group, Use of / Development of single site
capabilities. Second, some drivers consist in evaluating the capabilities of a location of
a manufacturing facility, knowing that the scope of possible locations is limited to the
nodes of the network, but could be possibly extended through new plants, joint
ventures, or partnerships. These drivers are thus forming a new group, Use of /
development of the network configuration capabilities. The next group that can be
identified is Use of / development of network coordination: this group of drivers
contains the drivers aiming at evaluating the implications of a possible solution for the
capabilities of the whole network, focusing on the links between the entities and the
coordination between them inside the network. However, these last two groups are
similar in the sense that they are both related to the evaluation of the network
capabilities, thus forming a larger group Use of / Development of network capabilities.
Finally, the last group contains the drivers consisting in evaluating the ability to
provide a financial advantage for the company, forming the group Use of /
Development of financial capabilities. The initial group of drivers is now split into
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four groups. Each group contains the drivers that have a common similar feature.
These specific features also permit to distinguish one group from the other.
The presentation of the identified groups is summarized in Table 6-9.
Group Categories
Decision context and environment Legislation requirements
Market characteristics
Product characteristics







Use of / development of the network
configuration capabilities
(1/2 sub-group of  Use of / development
of network capabilities)
Favourable production, economic, political factors
Access to strategic targets
Proximity to customers and suppliers
Use of / development of the network
coordination capabilities






Use of / development of financial
capabilities
Cost per unit
Ability to manage cash flows
Net present value
Product manufacturing location decision Product manufacturing location decision
Table 6-9: Table of the categorization results
Relationships results
The axial coding method also aims at uncovering the cause-effect relationships between
the categories. These relationships are identified by understanding the cause-effect links
between the coding labels. Bringing out these relationships permits to link the categories
together. The first relationships identified are the links between the four groups of drivers
and the product manufacturing location decision. The product manufacturing location
decision is led by the necessity to take account of the drivers, which aim to obtain a better
use of or/and to develop the manufacturing capabilities. Each group of drivers influences
the final decision. Table 6-10 summarizes the role of the factors for the decision for the
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ten cases, describing whether a property in a category, in the decision-making process,
had:
• A qualifying importance (2): a possibility has to be good enough along this factor
to be qualified as a possible solution (minimal requirement). In the case studies,
the qualifying factors are identified when a possibility is eliminated because it does
not fulfil a specific requirement, which is thus classified as qualifying criteria.
• A ranking importance (1): A possible solution is preferred among others according
to its values along the ranking factors. In the case studies, the ranking factors are
identified when a possibility is preferred to another because of a specific
characteristic, which is thus classified as ranking criteria.
• no importance (-): the factors has not been encountered in the case.
 (See Table 5-8 for the details of the names of the categories in column “Cat”).
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Table 6-10: Role of the drivers for the decision in the 10 cases
It appeared that the elements of the decision context and environment group are impacting
the importance of the drivers leading the decision. The relative importance of the drivers is
largely moderated by some external factors, classified into the decision context and
environment group, as presented in Table 6-11 (1 = impact, 2 = strong impact).
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003








































Table 6-11: Context/environment’s impacts on drivers
The cases studied present numbers of examples, detailing and justifying the conceptual
links between the decision context and environment group and the four groups of drivers.
These examples are given in Table 6-12. Thus, four links between the decision context
and environment and each group of drivers are identified.
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The legal aspect has a strong influence on the role of the drivers. For instance,
interdiction to import gives a main role to the access to market driver (1, 9). Import
regulations in the marketed country (import duties) create significant differences
between supply solutions and thus increase the importance of the cost driver (5, 7). The
legal possibility to register two sources to supply a product may allow considering a
dual source of supply and thus, gives a higher importance to the network flexibility
driver (3, 5). The legal requirements to register a product to be sold in the country can
significantly impact the lead-time driver needed to implement the solution when the
product is manufactured in a specific country (1, 3). The legal necessity to import from
countries manufacturing the product for their own market impact the possibility to
access to market driver or the necessity to source from a plant already manufacturing
the product (2 , 3 , 4, 5). The legal requirements in terms of packaging can impose a
specific packaging for a market, which gives determining role to the ability to serve the
market specificities driver to select a site (5, 8). Other informal restrictions may bring
difficulties to import in general (6) or from a specific country, giving an important role
to the country of origin driver (10).
Market
characteristics
The market characteristics impact the importance of several drivers in the decision. The
volume of sales and the market trend for instance can be linked with the need to choose
a flexible plant to serve the market specificities, to provide an appropriate MOQ
(category Ability to be flexible), (2, 3, 5, 7, 8), to choose a plant with an appropriate
batch size (2), or to aggregate with volumes in other plants (7, 8). The volume of sales
can also be linked with the expected fixed costs to be absorbed, if an in-house plant is
selected, or not absorbed if an external contractor is used (2, 3, 5, 6, 7). Other specific
features of the market are important. The current local margin impacts the importance to
lower costs (5, 7) and to be able to provide appropriate cash flows (3, 7). The market
acceptance to buy imported products (1, 2, 6) and structure/presence of local
competitors (generic products) impacts the importance of the access to the market driver
(1). The requested supply date of the first shipment impacts the importance of the
implementation lead-time (Ability to deliver the product) (2, 4, 7, 10).
Product
characteristics
Specific market needs in terms of product specifications are common. The pack size
depends for instance on the usages of the products (hospitals, outlets or over the
counter); the type of packaging has to vary according to the climatic conditions; the
practice to cut manually the blisters in the outlets or to sell whole boxes; the labels
change from one language to another, the expiration date required may be longer in
some markets. For instance, competition forces to refund the obsoletes for free for some
markets. All these specific product specifications affect the importance of the physical
ability to produce (6, 7), the ability to be flexible (8, 10) or the ability in terms of know-
how (3, 4, 5, 6), as few plants will be able to produce a specific product. They also
impact the role of the economies of scale driver, as specificities may go against the
possibilities to aggregate volumes, standardize among markets and use existing
investments (6, 7 , 8, 10). The strategic importance of the product for the company
impacts the importance of the ability to maintain quality (1, 9, 10) and to deliver the
product drivers (1, 6, 9).
Table 6-12: Details from the cases of the links context/environment to drivers
Finally, it appeared that the group use of / development of financial capabilities is linked
with the two groups of drivers: single site capabilities and network capabilities. Indeed the
financial capabilities are mainly derived from the other manufacturing capabilities; the
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potential financial advantages are mainly given by the potentials of the drivers from the
other groups, as detailed in Table 6-13.
Drivers Description
Cost per unit Costs for the marketed country are mainly deduced from the three categories of
drivers derived from plant capabilities, network coordination, and network
configuration. The components costs, transport costs, import duties, and taxes
are all mainly related to the network configuration (location of the operations
along the chain). The variable manufacturing costs are a complex result of the
facility capabilities: for instance, knowledge, flexibility, and quality; and of
the network configuration for the manpower costs for instance and finally of
the network coordination for the economies of scale with the possibilities to
concentrate volumes and standardize products. The fixed manufacturing costs
come mainly from the network coordination: investments in facilities and
capacity utilization rate or use of external contractor.
Local cash flow and
ability to manage cash
flows
Company margins are spread all over the international chain of operation. The
ability to adjust these margins is limited by the local legal requirements in
terms of minimal local margin in the manufacturing countries (network
configuration); the margin requirements of shareholders in joint ventures
impact the ability to manage cash flow (facility capabilities); the aggregation
of identical volumes (network coordination) for several markets (local market
of the manufacturing country and exports) also limits the possibility to adjust
the transfer price of imported components, as it will impact several cash flows.
Net Present Value:
corporate profits
The financial contribution of the project to the company is estimated through
the net present value of the project. It requires estimating the costs of
implementing the solution mainly derived from the facility capabilities
(investments, quality audits, quality test batches, and cost of longer time-to-
market). The yearly net earnings linked with the product/market includes the
expected sales (network configuration: access to the market and facility
capabilities: ability to serve market requirements) and costs which itself
includes delivery costs evaluated in the first row (all three groups) of this table
but also costs of inventories, derived from MOQ (facility capabilities:
flexibility) and transport lead-time (network configuration: proximity to
customers and suppliers).
Table 6-13: Details of the links from drivers to financial capabilities
Thus, two links from the network capabilities group to financial capabilities group and
from the single site capabilities group to financial capabilities group are identified.
The presentation of the relationships between the groups, identified in this section, is
summarized in Table 6-14. For the clarity of the table, the different groups previously
presented are numbered as follows: (0) Decision context and environment, (1) Use of /
Development of single site capabilities,  (2) Use of / development of the network
configuration capabilities, (3) Use of / development of the network coordination
capabilities, (4) Use of / development of financial capabilities, (5) Use of / development of
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the network capabilities, (6) Product manufacturing location decision. Thus, this table
presents the relationships from one group (i) to another (i’).
From group (i)
Type of relationship
(between i and i’)
To group (i’)
(1)
Use of / Development of
single site capabilities
(2)













Use of / development of
financial capabilities
(2)




Use of / development of
the network coordination
capabilities
Gives the value of (5)
Use of / development of
the network capabilities
(1)
Use of / Development of
single site capabilities
(5)
Use of / Development of
network capabilities
Gives the value of (4) Use of / development of
financial capabilities
(1)
Use of / Development of
single site capabilities
(5)
Use of / development of
the network capabilities
(4)








Table 6-14: Relationships identified between the groups
6.10. Stage findings and framework
Product manufacturing location decision in international manufacturing is about deciding
the location of each step of each manufacturing process in order to deliver a finished
product to defined markets. In the case of the pharmaceutical products, it consists in
deciding the manufacturing locations of the “incorporation into dosage form” step and of
the “packaging” step.
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A product manufacturing location decision, for a company delivering its products through
an international network of existing manufacturing facilities, namely in-house plants, joint
ventures, and external contractors, is driven by four distinct groups of drivers. The relative
importance between these four groups and between the drivers within a group is largely
decided by the context and the environment of the case studied.
The four distinct groups of drivers are (1) single site capabilities, (2) network
configuration capabilities, (3) network coordination capabilities, (4) financial capabilities.
The product manufacturing location decision seeks to benefit from and develop these
capabilities:
• Use of / development of single site capabilities (detailed in Table 6-15)
This group contains the drivers concerned with the evaluation of facilities in terms of
capability at the site level (existing plants, joint ventures, and external contractors).
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Facilities are available and are adapted according to the product specifications and the
volume. Some additional investments may be needed and have to be evaluated. The





Plants already manufacturing the product have a great advantage (no knowledge transfer,
guarantee of quality if the product is already sold on the local market for the importing
country). If no plant already manufacturing the product is available, plants manufacturing
similar products are preferred. In case of several plants already manufacturing the
product, the current product expiration date and the product storage conditions supported
by the plant are determinant to choose one possibility. The ability to export the product
(export experience, efficient customer service) or the cost to develop such a structure has




The site is able to carry out the manufacturing operations according to the quality
standard required. The risk of quality deviation over the long-term, especially for




The site is reliable in terms of service to deliver the expected quantity within efficient
lead-time (production lead-time). The risk of potential divergence with external
contractor for delivery priorities should be considered. The timeline to get ready to
deliver the first production must be estimated. The long-term sustainability of the site




The plant ability to serve market specificities (special artwork for the packaging) must be
evaluated. The volume flexibility, through the minimum order quantity, is a necessary
factor to estimate additional inventories (costs, issue for product with short expiration
date). The ability to provide a good sense of urgency can be estimated, with specific
considerations for contractors and some plants (poor customer service). Finally, the
flexibility to adjust the forecasted volume for uncertain demand is important (possibility
of expansion for in-house plants, limited possibility of further joint-investment for joint
venture, minimum volume contract, and back-up capacity contract with external
manufacturer).
Table 6-15: Inputs of Use of / development of single site capabilities
• Use of / development of the network configuration capabilities (detailed in Table
6-16)
This sub-group is a part of the Use of / development of the network capabilities group.
This sub-group contains the drivers concerned with the evaluation of the chain of
locations within the possibilities derived from the network configuration, which are
widened by the use of partners, for each step of the manufacturing process.
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The location (country and area) in which an activity is performed determines
some factors directly impacting the production: manpower costs, local taxation
(value-added tax, import duties on components, free trade agreement, and
government incentives), logistic support (ease of access, proximity to logistic
hub and infrastructure). The political instability presents a risk for the
investments, for the good delivery of the products and for the ability to maintain
appropriate corporate management. Finally, the signification of the “Made in
country X” on sales (negative, neutral, or positive impact) has to be estimated
and can be a critical factor for quality sensitive products.
Ability to access
strategic targets
The location of a manufacturing activity within the marketed country is a means
to overcome formal and informal barriers to access the targeted market. Formal
barriers are mainly interdiction to import. Informal barriers could be regulations
imposing a specific product definition fostering local manufacturing, or issue of
market acceptance to buy imported products. Manufacturing presence on the
market may not only increase sales, it may also improve the company’s image





The geographic dispersions of the manufacturing locations create non-value
added activities that should be minimized. For instance, they imply transport
between suppliers and the up-stream manufacturing entity, between the
manufacturing entities and finally between the down-stream entity and the
customers. The costs and lead-time given by this chain have to be estimated.
Necessary additional inventories at each entity associated with the transport lead-
time should be considered.
Table 6-16: Inputs of Use of / development of the network configuration capabilities
• Use of / development of the network coordination capabilities (detailed in Table
6-17)
This sub-group is a part of the Use of / development of the network capabilities group.
This sub-group contains the drivers concerned with the evaluation of a potential solution,
in terms of its implications, derived from the coordination and the inter-dependency
between entities for the whole network.
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Economies of scale can be obtained along three parameters: aggregation of
identical or similar volumes in a same site, higher standardization of products,




Economies of scope can be obtained with a better focus of activities. Fixed costs,
derived from the ownership of a site or the management of relationships with
and control over an external contractor (especially quality management), can be
absorbed through a wider range of products or stopped (Estimation of fixed costs
absorption and cost of free in-house capacity is necessary). Limiting the number
of different entities in the manufacturing chain and decreasing the complexity is
a means to reduce hidden management costs and interface issues enabling
economies of scope for the management. The number of suppliers for a market
can also to be contained. A market should prefer sourcing a product from a
current supplier in order to avoid additional management issues and
implementation transaction costs with a new supplier.
Network learning
ability
The learning ability within the network is characterized by internal learning
opportunities and external learning opportunities. Such opportunities appear
during knowledge transfer projects between facilities. It not only permits to re-
use solutions from one plant, it also creates contacts between people, which can
be useful to reach a higher efficiency and to solve problem by sharing solutions.
Outsourcing to innovative and best-of-class suppliers may increase the learning
opportunities, through necessary quality audits and collaborative works. New




Network flexibility is obtained when multiple (at least dual) source projects are
implemented. A market or a site can supply an item from several suppliers to
prevent sudden delivery issues or uncertain demand issue (short term). The
network flexibility can be improved for mid/long-term issues: choosing a
solution that creates new physical links between entities (new source of supply),
and widens the scope of possibilities for future decisions.
Table 6-17: Inputs of Use of / development of network coordination capabilities
• Use of / development of financial capabilities (detailed in Table 6-18)
This group contains the drivers concerned with the evaluation of solutions in terms of
potential financial advantages for the company. The value of the drivers in this category is
given by the three previous groups. The financial implications are derived from the single
site capabilities, the network configuration capabilities, and the network coordination
capabilities.
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Drivers Inputs
Cost per unit Costs for the marketed country are deduced from the previously mentioned
inputs. The sum of all cost elements has to be made: components costs, variable





Company margins are spread all over the international operation chain. The
ability to adjust these margins is an important factor, in order to minimize the
currency fluctuations and costly international cash transfers. Local legal
requirements in terms of minimal local margin, requirements of shareholders in
joint ventures impact the ability to manage cash flows, and aggregated volumes




The financial contribution of the project to the company is estimated through the
net present value of the project. It requires estimating the costs of implementing
the solution (investments, quality audits, quality test batches, and cost of longer
time-to-market). The yearly net earnings linked with the product/market are to be
estimated including the expected sales and costs (which itself includes delivery
costs evaluated in the first row of this table but also costs of inventories, derived
from MOQ and transport lead-time).
Table 6-18: Inputs for Use of / development of ability to provide financial advantages
The decision context and environment category contains external elements that indirectly
intervene in the product manufacturing location decision by impacting the relative
importance of the drivers mentioned in the four categories. In the decision-making
process, these elements are not dependent on the network and are considered as external




The legal context has to be drawn; For instance, the following factors have to be
collected:
Interdiction to import, import regulations in the marketed country (duties or product
specifications), legal possibility to register two sources to supply a product, legal
requirements to register a product to be sold in the marketed country, informal
restrictions to import in general or from a specific country.
Market
characteristics
The market characteristics have to be collected:
The volume of sales, market trend, and perspective of evolution of sales. Some
specific features of the market were identified such as current local margin, market
acceptance to buy imported products, the structure/presence of competitors and
specifically generic products, markets usages and climatic conditions, and finally the
requested supply date to implement the new source.
Product
characteristics
The product characteristics imposed by market needs have to be collected:
Specific market needs in terms of product specifications (pack size, type of
packaging, labels, and needed expiration date), the strategic importance of the
product for the company should also to be estimated.
Table 6-19: Inputs for the case context and environment category
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In summary, four groups of drivers were identified as driving the product manufacturing
location decision, namely: use of / development of single site capabilities, use of /
development of the network configuration capabilities, use of / development of the
network coordination capabilities and finally use of / development of financial
capabilities. The drivers aim at using more extensively the manufacturing capabilities and
developing them through the decision. The first three groups give the value of the last
group of drivers (use of / development of financial capabilities). Finally, the decision
context and environment largely impact on the relative importance of the identified drivers
in the decision, and dynamically groups the properties of the drivers as qualifying factors
and order-winning factors to evaluate a possible solution.
In other words, given a certain decision specific context and environment, the product
manufacturing location decision seeks to take the best advantage from the existing
manufacturing capabilities and to develop them at the greatest extent. Thus, it consists for
the manufacturing operations, in:
• Evaluating facilities in terms of their capabilities and selecting appropriate sites,
• Evaluating the capabilities derived from the network configuration and selecting
the appropriate geographic chain of locations,
• Evaluating the impact of a possibility for the capabilities derived from the network
coordination and selecting the possibility with the best impact for the whole
manufacturing network.
• Evaluating the potential financial advantages of a solution and selecting the best
solution in terms of its ability to provide financial advantage for the company.
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The findings can be summarized and graphically presented in the following framework
(Figure 6-2) for Product Manufacturing Location Decision, on which the three types of
identified relationships are shown.
Figure 6-2: Proposed framework for product manufacturing location decision
6.11. Revisiting the cases
The framework is in fact dynamic, as the importance of the links varies from one case to
another, according to the influence of the decision context and environment. As showed
by the case study and detailed in the previous section, the properties of the identified
drivers can be classified into two groups of factors: qualifying criteria and ranking
criteria. This permits to represent the cases, showing the dynamic importance of the
drivers that eventually lead to the decision. As shown below by the two simplified
representations of cases 3 and 6, the list of ranking criteria and qualifying criteria is
different in each case (see Figure 6-3 and Figure 6-4). The groups of manufacturing
capabilities that are strongly leading the decision, as they contain qualifying criteria, are
represented in bold in the figures. More detailed graphs for all the cases were established
to illustrate this mechanism and are enclosed as appendices.
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Figure 6-3: Simplified representation of case 3
Figure 6-4: Simplified representation of case 6
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The split of the criteria into the two categories, qualifying criteria and ranking criteria
categories is largely given by the decision context and environment. Only a limited list is
constituted of qualifying criteria and is relevant in one case to eliminate options that do
not match with the minimal requirements. Thus, defining this case specific list of
qualifying criteria from the influence of the decision context and environment permits to
reduce the number of possibilities studied in details, reduce the amount of data collected
and the resources needed in the decision-making process.
Next, we discuss the possible evolutions and generalisation of these research findings.
Firstly, we consider a change in the external situation and secondly, we consider a change
in internal situation.
First, the study showed that the decision context and environment influence the relative
importance of the drivers. The case study revealed that they are defined by the properties
of three groups: legislation requirements, market characteristics and product
specifications. As we only studied one company, it might be assumed that other factors
could influence the entire manufacturing location decision process. However, these three
groups are general concepts in which new factors describing the firm’s external
environment and context (or situation), can be included. For instance, a monopoly
situation, which can be classified as a market characteristic, is usually determined by
national entry barriers (legislation requirements), an innovative new product (product
specification) or the absence of competitors for a specific market (market characteristic).
Thus, it seems reasonable to classify the monopoly situation factor within one of the three
groups according to the actual situation. This factor, as part of the decision context and
environment, obviously has an impact on the relative importance of the location decision
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drivers: this company might rely on its existing facilities that have sufficient experience
and capacity; it may not try to establish new manufacturing positions nearer to other
markets, as it has little incentive to improve the delivery of products to these markets. It is
likely that, the manufacturing network characteristics of a company enjoying a monopoly
situation, will be different from the case of a market-based situation. Thus, the relative
importance of the location decision drivers is modified and induces another manufacturing
network. However, the monopoly case seems to fit the presented research principles and in
particular the decision process given by the framework. Of course, such generalisation
have to be studied and refined in further research.
Second, specific corporate strategic thrusts, which is an internal element of a firm, might
affect the manufacturing location decision, but is not captured by the way the research
methodology has been defined (c.f. research unit of analysis) . However, it seems
reasonable to state that strategic thrusts should have a grounded justification in order for
companies to reach optimal location decisions. Such strategic thrusts are usually based on
the business environment, in particular market characteristics, product specifications and
legislation requirements. In the pharmaceutical sector, a firm’s corporate strategy usually
leads to a trade-off between cost and quality, which might vary from one company to
another. The cost of not “doing quality” is determined by the market that the company
wants to target (e.g. branded good quality products for the upper class market and generic
products for lower margin markets) and/or legislation requirements (e.g. impossible to
enter the U.S. if not audited by the Federal Drug Administration). Thus, it appears that
grounded strategic thrusts are justified by the decision context and environment.
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Even within the same industry, companies will have their own interpretation of the context
and environment. For instance, companies might not have the same estimate on a new
market potential as they do not have the same information and the same experience. As
presented previously, classifying the different criteria affecting location decision is an
important step during the decision making process. Different strategic thrusts will affect
the relative importance of the location drivers as qualifying and ranking criteria. The list
of criteria itself might also vary from one company to another. Such differences in the
classification and the list of criteria imply differences in the network configuration,
explaining why different companies might choose different solutions. As a conclusion, it
can be reasonably implied that manufacturing location decisions might vary from one
company to another according to the way they each classify qualifying and ranking
criteria. This classification depends on the company’s strategic thrusts, themselves
justified by the company’s context and environment or the way the company interprets the
business environment. Although this extrapolation approves the research analysis, further
research should be conducted to validate this argument.
6.12. Conclusion
This chapter permitted to reveal that a product manufacturing location decision is largely
driven by the potential benefits drawn from the exploitation and from the development of
the company manufacturing capabilities at both a plant level and a network level. A list of
drivers detailing the manufacturing capabilities for the pharmaceutical industry was
established. More importantly, it permitted to identify and detail the influence of the
decision specific context and environment, specified by legislation requirements, markets
characteristics, and product characteristics, on the role of the previously identified
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drivers. A framework was developed to represent these contributions. The importance of
the drivers is dynamic, varying from one case to another according to the case specific
factors. The criteria permitting to evaluate the drivers for the potential solutions are thus
classified into qualifying criteria and ranking criteria.
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7. Methodology development and theory validation
7.1. Introduction
This chapter aims to develop a methodology or process tool from the previously presented
framework and to validate the relevance of this tool and its theoretical contents.
7.2. Methodology development
A tool directly derived from the theoretical contributions presented in the framework was
proposed in the form of workbook to help managers to tackle product manufacturing
location decision. The workbook, enclosed in the appendices, aims to give practical
understandings of product manufacturing location decision and to serve as a practical tool
for the managers to solve these issues. It contains a 5-steps process to organize the
decision-making process (see Figure 7-1).
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 Case identification
Product for defined markets
List of criteria
to evaluate the 
manufacturing 
capabilities
List of qualified chains
Step 5




List of chains List of requirements
Identify possible chains of 
location based on 
geographical locations and 
types of operation (i.e. 
wholly owned, joint -
venture or contractors)
Identify the requirements












Which chains meet 
the qualifying 
criteria?
Which chains meet 
the ranking criteria, in 




Sort criteria to qualifying 
and ranking categories 
based on decision context 
and environment
Figure 7-1: 5-steps tool for the decision-making process
These five steps constitute the logical process of the dynamic framework exposed in the
previous chapter. As shown Figure 7-1, steps 1 and 2 can be done in parallel or one before
the other. Then the following steps have to be done in order, step 3, step 4, and finally step
5. The steps are
• Step 1: This step consists in exploring the potential candidates for supplying the
markets with the case product. This is to say, it aims at identifying all the chains of
locations for the manufacturing operations (a chain is the sequence of locations: active
principle – manufacturing site – packaging site – market)
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• Step 2: From the identification of the case (product and pre-defined markets), this
step aims to describe the decision context and environment: legislation requirements,
market specifications, and product specifications.
• Step 3: From the decision specific context and environment, step 3 aims to identify
the specific importance of the criteria evaluating the manufacturing capabilities of a
solution. It permits to list the criteria into qualifying criteria and ranking criteria. The
list of criteria was presented in the previous chapter. It is the list of properties
identified as elements driving the decision in the mapping stage and is also given at
the end of the workbook.
• Step 4: This step includes the data collection in order to evaluate the value of a
solution along the qualifying criteria. Once the data is collected, the possible
candidates matching with the minimal requirements are selected for further enquiries
and constitute the remaining list of qualified candidates.
• Step 5: The last step consists of collecting the necessary data to evaluate the solutions
for the ranking criteria. Then it uses the remaining criteria to bring out pros/cons
among the qualified candidates and eventually rank them.
Figure 7-1 specifies the type of chart element in the decision-making process action,
evaluation, or outcome. However, this proposed tool is a guide for decision-making and
by itself is not sufficient to give the best answer. Rather, the tool facilitates identifying the
best decision, by ensuring a rational decision-making process, by detailing what are the
factors that have to be taken into account and how they are inter-related. For instance, the
split of criteria in two categories mentioned in Step 3 highly depends on the understanding
and experience of the managers, while the workbook can only give the possible cause-
effect relationships, which were identified from the previous cases.
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
125
7.3. Theory validation
The theory presented in this research was validated by two means. Firstly, a comparison
with previous tools permitted to show the advantages of the proposed tool and the
improvements achieved. Secondly, expert judgment permitted to ensure the usefulness of
this tool in practice and to validate the contents by relying on their experiences about
location issues.
Comparison with previous tools
As mentioned in the literature review, current tools are either quantitative or qualitative.
Quantitative tools, based on optimisation methods, do not take into account qualitative
factors that are often the determinants in such decisions. On the other hand, existing
qualitative tools are either poor in describing the relevant elements (weight-score model),
either focus on location decision as an independent plant without having a network
perspective, which has been found to be important from the case studies. In contrary, the
proposed tool permits to integrate both quantitative and qualitative factors in the decision-
making process. Besides, a detailed list of factors is given to ensure that it is directly
useful for the managers unlike the weight-score model principle proposed by Meredith
(1992). Finally, this tool includes the network perspective, in the list of factors to be
considered, integrating both configuration and coordination, and constituting a significant
improvement compared to previous tools.
Expert judgement
Asking for feedback from practicing managers, methodology known as “expert
judgement” is a commonly used method to answer an issue. Cooke (1991) studied the
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uncertainties behind such methodology. Dalkey (1969), Linstone and Turoff (1975)
proposed the Delphi method to capture expert opinions. Capturing “expert judgements”
was used to investigate the validity of this tool and its usefulness compared to previous
processes. This methodology aiming to validate research contents relies on the experience
of the respondents. Collecting the feedback from managers also permitted to evaluate
whether the proposed tool and its theoretical foundations answered to the research
question. A small questionnaire enclosed in appendices was developed to capture these
data, however, a large part of the data came from open questions. The questions aimed to
validate:
• The usefulness of such tool (how of the research question), mainly the process and
its advantages.
• The theoretical contents (why of the research question), mainly the mapping results
(list of factors) and their relationships.
• Finally the overall improvements possible with the workbook.
Seven practicing managers of the company, concerned with location decisions, were asked
to read the workbook and give their opinions through the basic questionnaire and open
comments. Though it does not have any statistical value, from a qualitative point of view
it still gives a good picture about the relevance of the tool. The list of the function of the
respondents is given in Table 7-1.
Respondents Designation
A Head of Supply-Chain Asia-Pacific
B Supply-Chain manager Philippines
C Supply-Chain manager Korea
D Supply-Chain manager Asia-Pacific
E Head of Industrial Operations Asia-Pacific
F Financial controller Industrial Operations Asia-Pacific
Table 7-1: Questionnaire respondents
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The results obtained in the questionnaire are presented below.
The 5-step tool
The following questions permitted to evaluate the tool:
• The 5-step process contributes to organize the decision-making process and ensures













Figure 7-2: Expert judgement for question 1
• The 5-step process is effective (shortens the decision-making duration, reduces the













Figure 7-3: Expert judgement for question 2
• The 5-step process is practical (is easily understandable, is realistic, and gives results
which can easily be used). Ratings are given in Figure 7-4.
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Figure 7-4: Expert judgement for question 3
• The 5-step process contributes to counter prejudices or divergent personal opinions (it














Figure 7-5: Expert judgement for question 4
The theoretical foundations
The theoretical foundations were evaluated through the following questions:
• The annexes (list of drivers for the decision) lists all the elements needed to take the
decision. Ratings are given in Figure 7-6.
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Figure 7-6: Expert judgement for question 5














Figure 7-7: Expert judgement for question 6
• The workbook uncovers the network dimension of the product manufacturing location
decision and specific considerations for fully owned plant, joint venture and external
contractor. Ratings are given in Figure 7-8.
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Figure 7-8: Expert judgement for question 7
The overall tool, including process and theory
Finally, the overall tool was evaluated by the following question:
• The overall tool constitutes an improvement compared to the usages in practice and













Figure 7-9: Expert judgement for question 8
Discussion
Some improvements were suggested for the presented version of the workbook and were
included in the latest version of the workbook, enclosed in appendices. However, the tool
and its contents received a good approbation from the managers, with average opinions for
all the questions except one between agree and strongly agree. As stated by the Supply-
Chain manager Asia-Pacific,
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“Sourcing looks very difficult, the workbook is still concise and clear. I find it better than the
official process in our company”
For one question, evaluating the ability of the workbook to present long-term implications
of the decision, the average opinion of managers was between neutral and agree. A lower
rating on that question suggests that the long-term aspect has not been fully studied. It is
mainly due to the short period of study, which did not permit to foresee all the long-term
implications of a decision. Future research may include longer longitudinal studies to
evaluate the long-term implications of a manufacturing location decision.
The modifications that were added concerned the presentation and the explanation of
some elements in the workbook to highlight these elements that appeared to be missing,
according to the opinion of some managers. For instance, the Head of Supply-Chain Asia-
Pacific underlined the importance of mother plants (main site and historical site
manufacturing a specific product) and regional plants in the decision. However, these
types of plants have specific characteristics, which were already mentioned. Indeed a
mother plant is preferred because it has a better knowledge of the product: for instance,
reliability in the product manufacturing process and good stability data. Besides, as it is a
source for a large number of markets, it commonly has a higher level of economies of
scale than other plants manufacturing this product. Regional plants are preferred for
another reason, which is the possibility to increase regional volumes and thus increase
overhead and fixed cost absorptions. Another example of modification came from the
comment of the Supply-Chain Manager in Philippines:
“How does the tool consider a product that may have sales potential after “x” no of years? How
does it affect the current network decided upon?”
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However, the category sales and trend was already existing as an element of market
characteristics and constituting an important factor impacting the importance of the
drivers. Further details and example were added in the workbook to give a better
understanding of this point.
After these revisions we estimates, based on the judgements of experts, that the proposed
tool and the theory on which the tool is developed, bring improvements compared to the
current knowledge of manufacturing location decisions.
7.4. Conclusion
This chapter permitted to validate the research contents through comparison with the
current tools available about manufacturing location decision and expert judgement.
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This chapter first presents the implications of this research for the different fields
concerned, then the limitations of these contributions and possible future research
perspectives. Finally, this is followed by a summary of the research findings.
8.2. Discussion
This study, as explained in the literature review chapter, refers to three fields, product
manufacturing location decision, international manufacturing network and outsourcing /
supply-chain. This research has several implications for these fields, firstly, the literature
concerning product manufacturing location decision is impacted as the relative importance
of the decision factors was established to be dynamic and as the network perspective
including configuration and coordination. Secondly, for the international manufacturing
network literature, the network considered and their capabilities were extended to external
network (including joint ventures and external contractors).
Dynamic relative importance of factors in manufacturing location decisions
This research permitted to identify a new feature in manufacturing location decisions. The
relative importance of factors intervening in the decision is dynamic and varies from one
case to another according to the decision context and environment. In order to save
resources and improve the time to market, managers have first to establish the list of
relevant qualifying factors for one specific case and then to collect the data permitting to
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evaluate the different possibilities. On the other hand, a static understanding of the relative
importance of the factors (MacCarthy and Atthirawong, 2003) does not really permit to
solve efficiently location issues.
Network perspective for location decision: configuration and coordination
Previous works about product manufacturing location decision focused mostly on
configuration aspects. This research revealed that coordination aspects also have a
significant importance and are relevant considerations in the decision-making process. The
main elements in terms of coordination were the possibilities to develop economies of
scale and economies of scope. Economies of scale were potentially obtained through
aggregation of identical volumes across markets. It permitted to reach a better
amortization of specific investments. Possibilities to concentrate volumes by developing a
higher standardization of products were also studied and in some cases were indeed
possible and decided. Economies of scope were potentially obtained by trying to increase
the capacity utilization rate of manufacturing entities, thus helping to absorb fixed costs
and overhead costs, such as regional and worldwide top-management related costs, which
are not specifically related to one product. Reaching economies of scope also consisted in
avoiding duplication of activities, firstly, by concentrating operations at the same place
when possible, reducing purchasing costs, customer service and other hidden management
costs, secondly, by reducing the number of supplier for one manufacturing site or market.
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Extending manufacturing network capabilities to external networks
Existing literature on international manufacturing network was confirmed by this research
to be relevant to tackle product manufacturing location decision. The existing concepts,
concerning internal networks, were extended to include specific considerations for
external entities. For configuration capabilities, few extensions were needed as these
capabilities characterise the properties of a location more than the type of manufacturing
entity. However, the possibility to extend the boundaries of the network by establishing
joint ventures or by resorting to external contractors gave access to new locations that may
present new advantages. In terms of coordination, the main element to be added to extend
coordination capabilities was the issue of interface between different organizations
(Economies of scope): transactions with other organizations and management of these
relationships implied significant hidden costs, negatively impacting the economies of
scope. In terms of economies of scale, specific considerations are needed, as better
economies of scale were possible by relying on external contractors for specific
equipments with low volumes within the company and where the contractor was able to
aggregate volumes for several customers. Besides, the network flexibility capability
needed to be extended as an external network provides a wider scope of possible sources,
especially to implement a double source of supply for a market. Finally, the learning
ability is also impacted. External learning ability was potentially improved when the
company was also dealing with joint ventures and external contractors. Partners in joint
ventures may potentially brought external ideas within the company and compulsory
audits of external contractors allows the flow of new ideas for in-house plants.
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8.3. Limitations and future research
Despite the achievements, this research poses several limitations that could be addressed
in further research. These limitations include increasing the generalisability of the research
findings, testing the method in new real cases, and examining the long-term impact on
capabilities.
Increasing the generalisability of the research findings
By nature the outcomes of this research is subject to number of boundaries and future
researches would be needed to extend and refine the proposed concepts and theory beyond
these boundaries. As stated by Handfield and Melnyk (1998):
“Specifically, researchers must consider the possible effects of industry, organization size,
manufacturing processes, and inter-organizational effects in setting boundary assumptions
on their observations.”
Especially, the main boundary is given by the fact that only one company was studied,
which is quite common in this type of study and is justified by the fact that case studies
aim to explore and let new theories emerge. These theories could be refined in a second
step. At this stage, it is still questionable to generalise from one company to whole
pharmaceutical companies (which are managing an international manufacturing network
constituted by wholly owned plants, joint ventures and external contractors). However, it
could be validated by further case studies in other companies or by elaborating a
questionnaire for a large number of pharmaceutical companies. Future research could also
evaluate whether the proposed theory is relevant in other sectors of the manufacturing
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industry and refine these contributions to be more general and adapted to a larger number
of industries.
Testing the method in new real cases
The validation of the theory and the process was done through expert judgements. To
validate the method and make it more robust, it is necessary to implement the framework
(operationalised through the workbook) for new cases. The companies could decide to use
the workbook and the researcher capture the data permitting to validate and improve the
methodology. Indeed a methodology becomes robust once it has been used and refined
several times in different contexts.
Examining the long-term impact on capabilities
Due to the limited period of study, this research cannot ascertain that manufacturing
capabilities have been effectively impacted by the location decision, but can only state that
location decisions were driven by the potential benefits obtained from the use of or the
development of manufacturing capabilities. Long-term studies would be needed to see
how a location decision really impacts the manufacturing capabilities over the long-term.
8.4. Summary of the research contributions
Product location manufacturing decision is a source of competitive advantages as it
permits to optimise the benefits derived from the utilisation and the development of the
manufacturing capabilities. However, existing literature did not assess the evolution of the
issues. Tools helping managers for location decisions have now to take into account that
international companies are responsible for the operation of complex manufacturing
networks, geographically dispersed and constituted by different types of entities and
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organisations. The research contributions achieved by this research about this question,
and presented in this dissertation, are summarized as follows:
• The research confirmed and specified the importance of the manufacturing
capabilities in product manufacturing location decisions involving wholly owned
plants, joint ventures, and external contractors.
• It revealed that a product manufacturing location decision is largely driven by the
potential benefits drawn from the exploitation and from the development of the
company manufacturing capabilities at both a plant level and a network level. A list
of drivers detailing the manufacturing capabilities for the pharmaceutical industry was
established.
• More importantly, it permitted to identify and detail the influence of the decision
specific context and environment, specified by legislation requirements, markets
characteristics, and product characteristics, on the role of the previously identified
drivers. A framework was developed to represent these contributions.
• The importance of the drivers is dynamic, varying from one case to another according
to the case specific factors. The criteria permitting to evaluate the drivers for the
potential solutions are thus dynamically classified into qualifying criteria and
ranking criteria.
• These new understandings of the product manufacturing location decision constitute a
new perspective for managers, starting-point to develop better tools. A workbook to
present the theory and give a practical process into a 5-steps tool was developed. A
comparison with the current tools and expert judgements permitted to validate that the
proposed tool and its theoretical foundations are better than current tools.
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
139
References
Anderson E. and Gatignon H.A. (1986), “Modes of foreign entry: A transaction cost analysis and
propositions”, Journal of International Business Studies, Vol.17; No.3; p.1-25
Armistead C.G. and Mapes J. (1993), "The impact of supply-chain integration on operating performance",
Logistics Information Management, Vol.6; No.1; p.9-14
Atthirawong and MacCarthy (2002), “An application of the analytical Hierarchy Process to International
Location Decision-Making”, The 7th Annual Cambridge International Manufacturing Symposium, p.1-18
Bartlett C.A. and Ghoshal S. (1988), “Organizing for worldwide effectiveness: The transnational solution”,
California Management Review, Vol.30; No.1; p.54-74
Barmess A. and Cerny K. (1993), “Building competitive advantage through a global network of
capabilities”, California Management review, Vol.35; No.2; p.78-102
Barney J.B. (1991), “Firm resources and sustained competitive advantage” Journal of Management Vol.17;
No.1; p.99-120
Berry D., Towill D.R. and Wadsley N. (1994), "Supply-Chain Management in the electronics products
industry", International Journal of Physical Distribution & Logistics Management, Vol.24; No.1; p.20-32
Bhatnagar and Sohal (2004), "Supply-Chain competitiveness: measuring the impact of location factors,
uncertainty and manufacturing practices", Technovation (in press, available online 18 November 2003)
Birch S. (1998), “The Pharmaceutical outsourcing outlook 1998-2003”, Reuters Business Insight
Healthcare, Datamonitor PLC
Cohen M.A., Fisher M., Jaikumar R., (1989), “International manufacturing and distribution network: a
normative model framework”. In: Ferdows K (Ed), Managing International Manufacturing. Elsevier,
Amsterdam
Cooke R.M. (1991), “Experts in uncertainty: opinion and subjective probability in science”. New York:
Oxford University Press
Cooke J.A. (1997), "In this issue", Supply Chain Management Review, Vol.1; No.1; p.3
Colotla I., Shi Y., Gregory M. (2002), “Operation and performance of international manufacturing network
and capability perspective”; EurOMA 9th International annual conference, Copenhagen, June 2-4 2002.
Chris Voss Best Paper Award – Winner
Contractor F.J., Lorange P. (1988), “Why should firms co-operate?” in F. Contractor and P. Lorange (eds),
Co-operative Strategies in International Business, 3-30. New York: Lexington
Cua K.O., McKone K.E., Schroeder R.G. (2001), “Relationships between implementation of TQM, JIT, and
TPM and manufacturing performance”, Journal of Operations Management, Vol.19; p.675-694
Dalkey N.C. (1969), “The Delphi method: an experimental study of group opinions”, Report No. RM-
58888.PR, The Rand Corporation
Dicken P. (1992), “Global Shift: The internationalisation of economics Activities”, 2nd edn. Paul Chapman
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
140
Doll W.J. and Vonderembse M.A. (1992), “The evolution of Manufacturing System: towards the post-
industrial enterprise”, in C.Voss (ed), Manufacturing Strategy - Process and Content, Chapman and Hall
Ferdows K. (1989), “Mapping International Factory networks”, in Ferdows, K. (ed) Managing International
Manufacturing, Elsevier Science Publishers
Ferdows K. (1997a), “Made in the world: The Global spread of production”, Production and Operations
Management Vol.6; No.2; p.102-109
Ferdows K. (1997b), “Making the Most of Foreign Factories”, Harvard Business Review, Vol.75; No.2;
p.73-87
Friedman J., Gerlowski D. and Silberman J. (1992), “What attracts foreign multinational corporations?
Evidence from branch plant location in the united states”, Journal of regional science, Vol.32; No.4; p.403-
418
Grant R.M. (1991), “The Resource-Based Theory of Competitive Advantage: Implications for strategy
Formulation”, California Management Review (spring); p.114-135
Grant R.M. (2002), “Contemporary Strategy Analysis”, 4th edition, Oxford, UK: Blackwell
Hayes R.H., Wheelwright, S.C. (1984), “Restoring our Competitive edge Competing Through
manufacturing”, New York: john Wiley & Sons
Handfield R. and Melynk S. (1998), “The scientific theory-building process: a primer using the case of
TQM”. Journal of Operations Management Vol.16; No.4; p.321-340
Hanna M., Newman W.R. (2001), “Integrated operations management: adding value for customers”. Upper
Saddle River, NJ: Prentice Hall
Hertz, S. and Alfredsson, M. (2003), "Strategic development of third party logistics providers", Industrial
Marketing Management, Vol.32; p.139-149
Hitomi K. (1994) “Manufacturing Systems: past, present and for the future”, International Journal of
Manufacturing System Design. Vol.1; No.1; p.4
Hodder J.E. and Dincer C.M. (1986), “A multifactor model for international plant location and financing
under uncertainty”, Computers & Operations research, Vol.13; No.5; p.601-609
Jungthirapanich C. and Benjamin S. (1995), “A knowledge-based decision support system for locating a
manufacturing facility”, in IIE Transactions, Vol.27; No.6; p.789-799
Karlsson C. (2003), “The development of industrial networks: Challenges to operations management in an
extraprise”, International Journal of Operations & Production Management, Vol.23; No.1; p.44-61
Linstone H.A. and Turoff M. (1975), “The Delphi Method: Techniques and applications”. Reading, MA:
Addison-Welsey
Leonard-Barton D. (1990), “A dual methodology for case studies: synergistic use of a longitudinal single
site with replicated multiple sites”, in Organisation Science, Vol.1; No.3; p.248-266
MacCormack A., Newman L. and Rosenfield (1994), “The new dynamics of Global Manufacturing Site
Location”, Sloan Management Review, Vol.35; No.4; p.69-80
MacCarty B.L. and Atthirawong W. (2003), “Factors affecting location decisions in international operations
– a Delphi study”, International Journal of Operations & Production Management, Vol.23; No.7; p.794-818
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
141
Makadok R. (2001), “Toward a synthesis of the resource-based and dynamic-capability views of rent
creation”, Strategic Management Journal Vol.22; p.387-401
McIvor (2000), “A practical framework for understanding the outsourcing process”, Supply chain
management Vol.5; No.1; p. 22-36
Meijboom B. and Vos B. (1997), “International manufacturing and location decisions: balancing
configuration and co-ordination aspects”, International Journal of Operations & Production Management,
Vol. 17 No. 8, 1997, pp. 790-805
Meredith J. (1992), “The management of Operations: A conceptual emphasis”, fourth edition, John Wiley &
Sons
Miles M.B. and Huberman A.M. (1994), “Qualitative data analysis: an expanded sourcebook”, Sage
production editor: Rebecca Holland
Min, H. and Melachrinoudis, E. (1999), "The relocation of a hybrid manufacturing / distribution facility
from supply-chain perspectives: a case study", Omega, Vol.27; p.75-85
Nagurney A., Cruz J., and Matsypura D. (2003), "Dynamics of Global Supply-Chain Supernetworks",
Mathematical and Computer Modeling, Vol.37; p.963-983
Oliff M.D., Arpan J.S. and DuBois F.L (1989), “Global Manufacturing Rationalization: The design and
Management of factory networks”, in K. Ferdows (ed) Managing International Manufacturing, Amsterdam:
Elsevier
Piachaud B.S. (2002), “Outsourcing in the pharmaceutical manufacturing process: an examination of the
CRO experience”, Technovation Vol.22; p.81-90
Pongpanich C. (1999), “Insights into product manufacturing location decisions”, Unpublished PhD Thesis,
Centre for International Manufacturing, University of Cambridge
Porter M.E. (1986), “Competition in global industries”, edited by Michael E. Porter, Harvard Business
School Press
Prahalad, C.K. and Hamel, G. (1990), “The core competence of the corporation”, Harvard Business Review,
Vol.68; No.4; p.79-91
Probert D. (1996), “The practical development of a make or buy strategy: the issue of process positioning”,
Integrated Manufacturing systems, Vol.7; No.2; p.44-51
Quinn, J.B. and Hilmer, F.G. (1994), “Strategic outsourcing”, Sloan Management review, Vol.35; No.4;
p.43-55
Revelle C. and Laporte G. (1996), “The plant location problem: new models and research prospects”,
Operations research, Vol.44; No.6; p.864-874
Riggs, J. (1976), “Production systems: planning, analysis, and control”. Santa Barbara: Wiley
Roberta S.R., Bernard W.T. (1995). “Production and operations management: focusing on quality and
competitiveness”. Englewood Cliffs, N.J.: Prentice-Hall
Rudberg M., Olhager J. (2003), “Manufacturing networks and supply chains: an operations strategy
perspective”, Omega, Vol.31; p.29-39
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
142
Schroeder R.G., Bates K.A., Junttila M.A. (2002) “A resource-based view of manufacturing strategy and the
relationship to manufacturing performance”, Strategic Management Journal, Vol.23; p.105-117
Sheu, J.B. (2003), "Locating manufacturing and distribution centers: An integrated supply chain-base spatial
interaction approach", Transportation Research Part E, Vol.39; p.381-397
Shi Y. and Gregory M., (1998), “International Manufacturing Networks – to develop global competitive
capabilities”, Journal of Operations Management, Vol.16, p.195-214
Shi Y., Fleet D. and Gregory M. (2002), “Global Manufacturing Virtual Network and its Position in
Manufacturing Systems”, The 7th Annual International Manufacturing Symposium: Restructuring Global
Manufacturing, p.197-205
Shumpeter J. (1950), “Capitalism, Socialism, and Democracy”, New York: Harper
Slack N. and Lewis M. (2002), “Operations strategy”, Harlow: Prentice Hall
Snow C.C., Miles R. E. and Coleman, H. J. (1992), “Managing 21st Century Network Organizations”,
Organizational dynamics, Vol.20; No.3; p.50-20
Stalk, G., Evans P. and Shulman L.E., (1992), “Competing on capabilities: the new rules of corporate
strategy”, Harvard Business review, Vol.70; No.2; p.54-66
Strauss A. and Corbin J. (1990), “Basic of Qualitative research: Grounded Theory Procedures and
techniques”, Sage
Sule, D.R. (1988), “Manufacturing facilities: location, planning, and design”, ed. D.R. Sule. Boston: PWS-
Kent Pub. Co
Syam, S. (2002), "A model and methodologies for the location problem with logistical components",
Computers & Operations Research, Vol.29; p.1173-1193
Tombak M.M. (1995), “Multinational plant location as a game of timing”, European Journal of Operational
Research, Vol.86; p.434-451
Tyan, J.C. ; Wang, F.K.; Du, T.C. (2003), "An evaluation of freight consolidation policies in global third
party logistics", Omega; Vol.31; p.55-62
Vos G. (1991), “A production-allocation approach for international manufacturing strategy”, International
Journal of Operations & Production Management, Vol.11; No.3; p.125-134
Voss C., Tsikriktsis N., Frohlich M. (2002), “Case research in operations management”, International
Journal of Operations & Production management, Vol.22; No.2; p.195-219
Welch, J.A. and Nayak, P.R. (1992), “Strategic sourcing: a progressive approach to the make or buy
decision”, Academy of Management Executive, Vol.6; No.1; p.23-30
Williamson O.E. (1985), “Markets and hierarchies”, Free Press, New York, NY
Yin, R.K. (1994), “Case study research: design and methods”, Vol. 5, 2nd edition, Thousand Oaks, CA: Sage
publications
Yoon K. and Hwang C. (1985), “Manufacturing plant location analysis by multiple attribute decision
making; Part 1-single plant strategy Part 2 - multi plant strategy and plant relocation”, International Journal
of Production Research, Vol.23; No.2; p.345-359 and p.361-370
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
143
Appendices
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
144
A. The pharmaceutical manufacturing process
Figure 0-1 gives a simplified overview of the pharmaceutical manufacturing process. In
this dissertation, the term manufacturing step states for the “incorporation into dosage
form” box and the term packaging step states for the “packaging” box.
Figure 0-1: Overview of the pharmaceutical manufacturing process
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B. Semi-structured interview protocols for retrospective cases
Interview protocol for pilot cases
Starting from the research question, this paragraph details the data needed to be collected
during the interviews. These are indeed the core of the data collection.
As presented in the literature review chapter, the research question is:
How can multinational firms efficiently and practically select a location to manufacture a
product, among existing wholly owned plants, joint ventures, and local contractors, with
the aim to build long-term strategic manufacturing capabilities?
This research question was in fact formulated by three points presented in the literature
review chapter.
1. Which is the most appropriate chain of operations among existing wholly owned plants,
joint ventures, and external contractors?
2. How to consider long-term strategic manufacturing capabilities in the decision?
3. How to stay efficient and practical in the process of decision-making?
For each of this point, several sub-questions are raised by the light of the literature review
and the exploratory case chapter. These questions are detailed in this section to make sure
that all the aspects are covered during the interview:
1. Some general questions would have to be covered first, to understand the case:
What is the manufacturing process? What is the product and for which market is it
manufactured? What is at stake in the location case? What are the prerequisite
expectations regarding the manufacturing? Could the manufacturing process be
split into several layers, implying different location decision for each layer? The
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literature review also permitted to identify the issues of the list of factors and their
relative importance for the selection. The exploratory case chapter permitted to
suggest that the relative importance of the factors might vary from one case to
another. The different questions to be addressed to answer this point are: What are
the different possibilities to be considered? How do we select the best one? What
are the factors to be applied to select a solution? What is the relative importance of
those factors? Are the factors and their importance varying from one case to
another? Why?
2. This point aims at understanding the long-term implications of the decision that
have been considered or missed during the case. It raises the following questions:
Is there any criterion missing? Especially have we evaluated the impact on the
long-term of the decision? Strategically, what do we miss and/or benefit from
when choosing a possibility? Especially what are the strategic impacts to choose a
joint venture or an external contractor solution?
3. This point refers to the decision-making process and more precisely its
organization, its efficiency, and its usability for the managers. The question to be
covered are: What are the steps? Is the current process clear and easy to tackle? Is
the data needed available or could it be available? Knowing that a firm has limited
resources, trade-offs between the level of details to compare different possibilities
and the resources required may occur. It raises the following questions: What is the
expected length of the preparation period before taking a decision? How many
factors are acceptable? What is the acceptable number of possibilities to study? Do
we have to study all the possibilities? If not, how and why do we eliminate some
possibilities?
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These questions could be classified into four themes, forming the structure of the semi-
structured interview: The context of the decision, the scope of the decision, the
argumentation of the decision, and the process of the decision.
• The context of the decision:
What is the product and for which market is it manufactured? What is at stake in the
selection? What is the manufacturing process?
• The scope of the decision:
What are the different possibilities to be considered?
Especially among the contractors, what is the scope of the possibilities? What is the
acceptable number of possibilities to study? Have we to study all the possibilities? If not
how and why do we intuitively, eliminate some possibilities? Could the manufacturing
process be split into several layers, implying different location decision for each layer?
• The argumentation of the decision:
What are the criteria to be applied? How many criteria are acceptable? Is there any
criterion missing? What are the prerequisite expectations regarding the manufacturing? Do
we have evaluated the impact on the long-term of the decision? What is the relative
importance of those criteria? Are the criteria and their importance varying from one case
to another and why? Is the data needed available or could it be available?
• The process of the decision:
What are the steps? Is the current process clear and easy to tackle? What is the expected
length of the preparation period before taking a decision?
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Second interview protocol for main cases
A more precise interview protocol was developed for the main retrospective cases,
according to the issues and objectives that have to be covered. The main retrospective
cases aim:
• To validate and refine the identified categories. In order to gather this information,
several open questions, similar to the exploratory case stage, would permit to bring
out possible new categories or new properties of identified categories. Few more
focused questions based on the up-to-date knowledge permit to test the relevance
of the categories previously discovered.
• To understand the links between the categories. In order to gather this information,
a third group of questions would focus on detailing the decision process, aiming to
understand how the drivers, in terms of importance lead to the final decision.
The semi-structured interview protocol is detailed in the following paragraph.
1. Open questions Aiming to let all the events emerge in order to discover new categories
or properties, these questions are rather open. The questions should cover all the process
of the decision and are similar to the pilot cases interview protocol:
- Origin/causes of the case,
- Identification of the potential solutions,
- Pre-elimination of some possibilities,
- Comparison of the solutions,
- Argumentation for the decision
- Final decision
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2. Validation questions In order to review the relevance of the previously discovered
categories and their properties, these questions should cover each identified category.
- Case context / Environment
- Product manufacturing location decision
- Drivers (Use of facilities, Develop Economies of scope…)
3. Relationship-building questions These questions aim to provide the necessary data to
understand the importance of the drivers and the links between the categories.
The questions have to cover:
- Link between context/environment and drivers. Especially how the
context/environment influences the relative importance of the drivers in the
decision.
- Link between drivers and decision. What is the importance of each driver? How a
driver intervenes the decision process?
- Link between context/environment and decision. Does the context/environment
affect directly the decision?
- Link among the drivers. Similarities and differences among the drivers. What are

























































































































































































































































































































































































































































































































































































MANUFACTURING LOCATION DECISIONS                          MATHIEU PELLERIN                                                                 2003
IN THE PHARMACEUTICAL INDUSTRY























































































































































































































































































































































































































































































































































































































































































































MANUFACTURING LOCATION DECISIONS                          MATHIEU PELLERIN                                                                 2003























































































































































































































































































































































































































































































































































































































































































































































































































MANUFACTURING LOCATION DECISIONS                          MATHIEU PELLERIN                                                                 2003




































































































































































































































































































































































































































































































MANUFACTURING LOCATION DECISIONS                          MATHIEU PELLERIN                                                                 2003





























































































































































































































































































































































































































































































































































































































































































































































































































MANUFACTURING LOCATION DECISIONS                          MATHIEU PELLERIN                                                                 2003










































































































































































































































































































































































































































































































































































































































MANUFACTURING LOCATION DECISIONS                          MATHIEU PELLERIN                                                                 2003





















































































































































































































































































































































































































































































































































































































































































































































































































MANUFACTURING LOCATION DECISIONS                          MATHIEU PELLERIN                                                                 2003











































































































































































































































































































































































































































































































































































































MANUFACTURING LOCATION DECISIONS                          MATHIEU PELLERIN                                                                 2003



































































































































































































































































































































































































































































































































































MANUFACTURING LOCATION DECISIONS                          MATHIEU PELLERIN                                                                 2003
















































































































































































































































































































































































































































































































































































































































































































































































































MANUFACTURING LOCATION DECISIONS                          MATHIEU PELLERIN                                                                 2003
IN THE PHARMACEUTICAL INDUSTRY
MANUFACTURING LOCATION DECISIONS                                  MATHIEU PELLERIN   2003
IN THE PHARMACEUTICAL INDUSTRY
160
D. Questionnaire to evaluate expert judgement
Questionnaire: Evaluation of the proposed methodology for sourcing decisions
Function in the company:  
The 5-steps workbook process Strongly disagree -----> Strongly agree
contributes to organize the decision-making process, and
ensures that no factor is forgotten.
-2 -1 0 1 2
is effective (shortens the decision-making duration,
reduces the need for resources, avoids to re-invent each
time).
-2 -1 0 1 2
is practical (is easily understandable, is realistic, and gives
results which can easily be used).
-2 -1 0 1 2
contributes to counter prejudices or divergent personal
opinions (It brings objectivity, thus helps to identify the
best solution).
-2 -1 0 1 2
Comments on the process
The workbook theoretical foundations Strongly disagree -----> Strongly agree
The annexes (list of criteria) lists all the elements needed
to take the decision.
-2 -1 0 1 2
The workbook uncovers the long-term implications of the
decision.
-2 -1 0 1 2
It uncovers  the network dimension of the product location
decision and specific considerations for fully owned plant,
joint-venture and external contractor.
-2 -1 0 1 2
Comments on the theoretical foundations
The overall tool (process + theory) Strongly disagree -----> Strongly agree
constitutes an improvement compared to the usages in
practice and gives a better understanding of the location
issues
-2 -1 0 1 2
Comments on the overall tool
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